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Sli'lMARY
The aim of this study was to investigate the effects of the 
rumen on the kinetics of drugs by measuring plasma and gastro-intestinal 
fluid concentrations of model drugs (weak acids and bases), after various 
routes of administration. The experimental animals used were Finn-Dorset 
sheep fitted with permanent ruminai, abomasal and duodenal cannulae, and 
the drugs chosen were rneclofenamate, an acidic drug, and levamisole, 
fenbendazole, oxfendazole and albendazole which are basic drugs.
All of the drugs studied were absorbed to some extent after 
oral administration. Levamisole only was absorbed fixim the rumen; 
absorption from this part of the gastro-intestinal tract was much slower 
than that from the more distal regions. For the other drugs studied, 
absorption from the rumen was negligible.
Passive diffusion of drug from the systemic compartment into 
the rumen, either across the rumen wall or via the saliva, was found to 
occur with levamisole and meclofenamate, but not with the benzimidazole 
drugs or their metabolites, Levamisole administered subcutaneously, 
and benzimidazole metabolites formed in the systemic compartment were 
found to diffuse into abomasal fluid, reaching higher concentrations than 
those found in plasma at the same time.
The kinetics of the benzimidazole drugs were found to be very 
slow, the drugs persisting in plasma and gastro-intestinal fluid for 
up to 9 days. This v/as attributed to the loiv water and lipid solubility 
of the drugs compared with that of levamisole and rrsclofenamate. Passage 
through the rumen,of the drugs studied,was found to slov/ the rate of 
absorption compared with that of drug administered directly into the
abomasum. Oral administration of each of the drugs studied resulted, on 
almost every occasion, in senne of the drug being delivered directly to 
the abomasum by,the action of the reticular groove. The extent of 
ruminai by-pass was variable and usually small. It did not appear to 
be consistent for any individual animal.
High concentrations of benzimidazole metabolites were found 
in plasma and in abomasal fluid after oral, intra-rum,inal and intra­
abomasa 1 administration of the parent drug. The site of metabolism of 
the benzimidazoles was investigated in vitro. On incubation with 
hepatic microsomes both sulfide orugs, fenbendazole and albendazole, wei-e 
oxidised to sulfoxides and sulfones. Reduction of fenbendazole 
sulfoxide (oxfendazole), and albendazole sulfoxide, also occurred 
during incubation in vitro with liver microsomesi both sulfoxides were 
found to undergo reduction to the sulfides on incubation with fresh 
ruminai fluid. Ho oxidation or reduction was found during incubation 
of sulfides or sulfoxides with abomasal fluid.
The anthelmintic activities of albendazole and its two major 
metabolites, albendazole sulfoxide and albendazole sulfone were 
compared by administration of the compounds in feed to rats infected with 
Nippostrongylus braziliensis. Albendazole sulfoxide was found to have 
similar anthelmintic activity to albendazole, and albendazole sulfone 
was found to be non-active. The relevance of these findings to the 
suggested mode of action of these riruzs is discussed.
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CHAPTER 1 
INTRODUCTIGN and LITERATURE REVIEW
There are an estimated 95 million cattle and 94 million 
sheep in Western Europe, the vast majority of which will receive some 
form of drug treatment, whether it be therapeutic or prophylactic, at 
some time during their lives. In 1977 the estimated value of
anthelmintic drugs alone used in these animals was in the region of 
£58 millions, and the world market value was something over £250 
millions. It is a little surprising in view of this large, 
relatively constant market that so little is apparently knov/n about 
the processes of absorption, distribution and elimination of drugs 
with regard to the ruminant animal, and in particular the effect of 
the rumen on both orally and parenterally administered drugs.
Little rationale is apparently used in the choice of 
dosage reginps which are largely determined on the basis of efficacy 
trials or on data from rnonogastric animals. A more reasonable 
approach would seem to lie in the determination of minimum effective 
concentrations of a drug and how to achieve these concentrations at 
the site of action of the drug. The oral route for administration 
of drugs is more convenient in many cases than the parenteral route 
avoiding pain, the risk of carcase damage from injection site 
necrosis, and also the necessity for sterility. For these reasons 
it is very widely used in rnonogastric species, but the possible 
effects of the rumen have precluded such wide usage in cattle and 
sheep, the exception being the anthelmintic drugs which are 
frequently administered as drenches.
Absorption of drugs from.the gastro-intestinal tract of
man and other rnonogastric animals has been studied in some depth and 
the processes involved are relatively well understood. The 
epithelial lining of the stomach and small intestine behaves as a 
classical cell membrane which is postulated to consist of a bimolecular 
layer of orientated phospholipid rrolecules forming a lipid matrix 
with polar heads aligned at both surfaces. Globular protein 
molecules are interspersed, with polar groups protruding into the 
aqueous phase at each side, and non-polar groups embedded in the 
matrix.
The cell membrane is permeable to the unionized form of 
lipid soluble molecules in solution which are absorbed by passive 
diffusion along a concentration gradient. The rate of passage across 
the membrane is determined by the lipid solubility of the drug. For 
example, increasing rate of absorption of different barbiturates 
from the rat stomach is in the same order as their increasing lipid-to- 
water partition co-efficients CSchanker, Shore, Brodie and Hogben,
1957], and correlation between rates of absorption of several weak 
organic acids and bases from the rat small intestine, and the lipid-to- 
water partition co-efficients of their unionized form, has also been 
demonstrated (Hogben, Tocco, Brodie and Schanker, 1958].
Since the unionized form of most drug molecules is the 
fraction available for absorption, the imposed concentration gradient 
along which passive diffusion occurs depends upon the degree of 
dissociation of the drug. This in turn is governed by the dissociation 
constant of the particular drug and the pH of the surrounding medium.
In general terms this means that only drugs which are weak acids or
weak bases are well absorbed since strong acids and bases are largely 
ionized at any pH encountered within the gut.
Weak acids such as barbiturates and some sulfonamides are 
readily absorbed from the stomach (pH 1-2] but weak bases such as 
quinine and aminopyrine are very poorly absorbed. If the pH of gastric 
contents is raised artificially basic drugs have an increased rate of 
absorption and acidic drugs a decreased rate of absorption (Schanker 
et al, 1957), The pH of the intestinal lumen is generally around 6.6 
and so weak bases are much better absorbed from this less acidic part of 
the tract. There is evidence for the existence of a more acidic region 
at the actual site of absorption by intestinal cells which is maintained, 
to some extent independently of the pH of intestinal contents, at a pH 
of 5.3 (Hogben et al, 1959), This effective pH was thought by these 
authors to explain why only weak acids with a pk^ value greater than 3 
and weak bases with a pk^ of less than 7.8 are well absorbed from the 
intestine; outwith these limits the low proportion of unionized drug 
severely reduces absorption.
The degree of ionization of any drug at a given pH is given 
by the Henderson-Hasselbalch equation - 
for a weak acid^
and for a weak base.
log base,,  ^ ^
 ^ unionizeo oase  ^a
where pk^ = negative logarithm of the acid dissociation constant.
Theoretically absorption across the gastro-intestinal mucosa
occurs until the concentration of unionized dreg in plasma is equal
to that in the gut (although for most drugs the total concentrations 
v^ ill be veiy different because the difference in pH causes different 
degrees of ionization). In practice this steady state equilibrium 
is not achieved because of distribution, metabolism and excretion of 
the drug, and passage of gut contents further along the tract.
Steady state concentrations have been measured experimentally in 
anaesthetized rats and the concentrations found were in agreement with 
the theory that the epithelial border has a slightly lower pH than 
intestinal contents (Hogben et al, 1958). The intestine, due to the 
greater surface area of its brush border, is the major site of 
absorption for most orally administered drugs; as mentioned earlier 
basic drugs undergo very little absorption in the stomach.
The theory of passive diffusion of lipid soluble, non­
ionized molecules does not, however, account for the rapid movement 
of small lipid insoluble molecules such as urea across rrombranes.
It is suggested that there are aqueous channels in the nrombrane 
through which lipid insoluble molecules and ions can pass. The rate 
of transfer in this case is dependent on size of the molecule, and 
in the case of ions, the charge carried. Small molecules undergo 
more rapid transfer than large ones. Most drug molecules are too ‘ 
large for this process to be quantitatively important in absorption.
Active transport mechanisms for certain molecules such as 
glucose, amino acids, pyrimidines and inorganic ions are known to 
exist in the small intestine. For drugs v/ith chemical structures 
very similar to these substances, there is evidence that absorption 
using these active transport processes can occur. Pyrimidines such
as 5-fluorouracil and 5-brorrouracil have been shown to be actively 
transported across the intestinal epithelium by the process which 
transports the natural pyrimidines uracil and thymine (Schanker and 
Geffrey, 1961), and several foreign sugars with structures similar to 
that of glucose are actively absorbed by the monosaccharide transport 
process of the intestine (Wilson and Landau, 1960).
This applies to relatively few drugs, however, and for the 
great majority passive diffusion of the lipid soluble unionized form 
is the only means of transfer across the gut wall.
ANATOMY OF THE RUMINANT STOMACH
The ruminant stomach in the adult animal is a voluminous sac 
occupying a large part of the abdominal cavity. The sac has four 
parts, the reticulum^rumen and omasum collectively termed the 
forestomach, and the abomasum frequently termed the true stomach.
The reticulum, the most cranial part, is largely continuous 
with the rumen and the two are often alluded to as the reticulo-rumen. 
The rumen has by far the largest volume of the four parts; it is 
partially divided into dorsal and ventral sacs by thick muscular 
invaginations of the walls, the anterior and posterior pillars of the 
rumen. Digesta enters the reticulo-rumen from the oesophagus at the 
cardia. The outflow of digesta from the reticulo-rumen is to the 
omasum via the small reticulo-omasal orifice situated on the medial 
wall of the reticulum^ ventral to the cardia. Running from the 
oesophageal opening across the medial wall of the reticulum to the 
reticulo-omasal orifice is a groove, the oesophageal or reticular 
groove. The groove has thickened edges which on contraction formi an 
extension of the oesophagus delivering ingested material to the 
omasum. The omasum is smaller than the reticulum in sheep; the 
reverse is true in cattle, A large omasal-abomasal orifice opens 
into the abomasum v/hich is similar to the rnonogastric stomach.
The mucous membrane of the parts of the forestomach has 
differing arrangements, although it is lined throughout by stratified 
squamous epithelium which is largely keratinized. In the reticulum 
the arrangement of the mucosa is honeycomb-like, thrown up into 
shallow folds forming the 'cells’ of the honeyconb. These cells
contain epithelial projections or papillae which are also present 
over much of the interior of the rumen. The mucous membrane lining 
the omasum extends into a series of deep folds or laminae, several 
different depths of which are recognized. These laminae also bear 
homy papillae, the function of which is almost certainly to reduce 
digesta to very fine particles.
The abomasal mucosa in contrast is lined by a sinrple 
columnar, glandular epithelium. It has fundic and pyloric regions 
similar to those of the rnonogastric animal. In the fundic region 
the mucosa forms extensive spiral folds, which greatly increase the 
surface area of the abomasum relative to that of the rnonogastric 
stomach.
FUNCTION OF THE RUMEN
The reticulo-rumen acts as a continuous fermentation vat 
in which vast numbers of micro-organisms degrade the dietary intake 
of the animal. The fermentation process produces the volatile fatty 
acids acetic, proprionic and butyric, from which the ruminant animal 
gets most of its energy supply. Ammonia, carbon dioxide and methane 
are also important end products of the fermentation. Conditions 
within the rumen are fairly stable under a given dietary regime. The 
pH generally is maintained at 5.5-6.5. The addition of large 
volumes of highly buffered alkaline saliva as much as 96-130 litres 
in 24 hours in cattle (Bailey, 1961), and 6-16 litres over the same 
period in sheep (Kay, 1960), maintains the volume of the contents.
Various estimations of the capacity of the reticulo-rumen 
have been made. Sisson and Grossman (1953) quote a figure of
25-60 US gallons (95-227 litres) in cattle end 4 US gallons (15 litres) 
in sheep. Warner and Flatt (1965) estimated a 500 kg cow to have as 
much as 100 kg of reticulo-rumen contents and a 50 kg sheep between 5 
and 10 kg. Neff-Davis, Davis and Powers (1975) estimated the total 
gastro-intestinal tract and contents of the goat to comprise 20% of 
total body weight; by,comparison the same figure for the dog- is given 
as 4 « 6" o •
The contents of the reticulo-rumen are largely water. The 
exact dry matter of the digesta varies according to the type of diet, 
frequency of feeding and also varies within different parts of the 
reticulo-ruminal sac. In cows fed hay once daily Evans, Pearce,
Burnett and Pillinger (1973) found the dry matter of the contents from 
different sites to vary between 3% and 15%.
Sanples from the dorsal sac had higher dry matter than those
from the ventral sac, illustrating the imperfect mixing of the contents.
a
Mixing occurs by^regular sequence of contractions of the 
various parts of the reticulo-rumen which serves to expel contents into 
the omasum, as well as give maximum exposure to the microbial digestive 
enzymes. Further contractions are associated with rumination and 
eructation. The papillae of the forestomach play a part in the fine - 
division of ingesta, as does the process of rumination by which the 
contents are re-masticated by the animal at intervals.
POSSIBLE EFFECTS OF THE RETICULO-RUMEN OU ACMINISTERED DRUGS
"The presence of a large fermenting bulk within the foregut 
constitutes a major factor by which the ruminant differs from other 
species in the distribution and fate of ingested and injected materials"
(Dobson, 19673,
The reticulo-rumen indeed constitutes a large bulk, and has 
a significant effect on the distribution of body fluids» Dobson 
(1967) estimated that the gut water of the ruminant forms a compartment 
equivalent to or greater in size than the rest of the extracellular 
fluid of the animal.
This large volume of fluid might be expected to affect the 
pharmacokinetics of both orally and parenterally administered drugs 
in a number of ways. The accessibility or otherv/ise of rurren fluid 
to parenterally administered drugs would make a considerable difference 
to the concentrations achieved after a given dose in other body 
compartments. Knowledge of the distribution of such drugs is of 
importance in the prediction of therapeutic dosage, especially if 
this is based on data from rnonogastric animals.
If passive diffusion of drugs between the reticulo-rumen 
and the systemic compartment does occur freely, then it would also be 
expected that weakly basic drugs would diffuse across the rumen wall 
in the unionized state, become ionized at the lower pH of ruminai 
fluid and thus accumulate in the rumen by this process of 'ion 
trapping’. Since many of the anthelmintics and antibiotics currently 
used are weak bases, the extent to which this occurs is also of 
importance.
Drugs entering the rumen by oral administration or from the 
systemic compartment are exposed to large numbers of micro-organisms 
>10^^ per ml (Warner, 1962) which have considerable powers of 
degradation. Certain drugs are known to be susceptible to microbial
10
activity. Chloramphenicol is one(Theodorides Dicuollo, Guarini 
and Pagéno, 1968) and trirrethoprim another (Nielson, Romvary and 
Ramussen, 1976). Passage of material through the rumen is slow, 
and so the duration of exposure to micro-organisms of both solid 
di-'ugs and those in solution can be considerable. Balch (1950)
found that the concentration of stained hay in the rumen of cattle
after its addition to the feed had fallen by 50% only after 40-48
hours had elapsed, and stained hay was detectable in the rumen for
5 days or more. Grovum and Williams (1973) found the average half- 
life of a fluid marker in the rumen of sheep to be 604 minutes 
and that of a particulate natter marker to be 811 minutes. The half- 
lives of the same markers in the abomasum were much shorter, 17 and 
37 minutes for fluid and particulate matter respectively.
As well as the possible effects of microflora on orally 
administered drugs the large volume of reticulo-ruminal fluid 
has a dilution effect on dissolved drug so that the concentration 
would be much lo%ver than if the equivalent dose was administered to 
the abomasum or to the rnonogastric stomach. Since the rate of 
absorption by passive diffusion is dependent partly on concentration 
gradient, even if absorption occurred froely from the rumen then it ' 
would be expected to be slower than that from the true stomach/small 
intestine. If the rumen has little or no absorptive capacity for 
drugs, the delivery of drug to the site of absorption(abomasum/small 
intestine) is slowed, so that the net effect is the same. For drugs 
with rapid elimination an excessively slow rate of absorption may mean 
that therapeutic concentrations are not obtained in the systemic
11
compartment in ruminant species.
Conversely the slow passage of orally administered drugs 
through the reticulo-rumen would increase the length of time available 
for dissolution of drugs admiinistered in the form of solids or 
suspensions. For drugs of low solubility this effect, together with 
the lai^e volume of the contents, may lead to an increased -bio- 
availability of such drugs in the ruminant compared with the mono- 
gastric animal, in which low solubility and shorter gastro-intestinal 
retention time can lead to incomplete absorption.
12
THE RETICULAR GROOVE
The reticular Coesphageal) groove is an anatomical feature 
of the ruminant stomach which allows swallowed liquids to pass directly 
from the oesophagus to the reticulo-omasal orifice, thus allowing it 
to by-pass the reticulo-rumen. In the nev'/born animal the reticulo- 
rumen and omasum are small in relation to the abomasum, undeveloped 
and apparently functionless. It has long been known that in young 
suckling ruminants ingested milk passes directly to the abomasum.
The function of the groove in the older animal and the 
stimulus for its closure have been the subject of several investi­
gations. The possibility of delivery of drugs, particularly 
anthelmintics, directly to the abomasum, avoiding dilution and possible 
degradation by the reticulo-rumen contents was realised by many early 
workers CClunies Ross, 1934, 1936; Mbnnig and Quin, 1935; Watson, 
1941).
It was thought by Colin C1Ô86) that closure of the groove 
during rumination was the means of delivery of digesta from the 
reticulo-rumen to the omasum and abomasum. Schalk and Amadon 
C1928), however, using animals with rumen cannulae reported that, in 
contrast to suckling animals, the groove did not regularly close in 
adult ruminants. Both these authors, and Trautmann and Schmitt 
C1933), observed that closure of the groove became less marked as 
the animal grev/ older, increasing amounts of milk passing to the 
rumen. Wester (1926) also noted that closure of the groove occurred 
more readily in younger animals. he postulated that constituents
13
of the milk, primarily sodium ions, were responsible for eliciting 
the response by contact with the mouth. From his experiments in 
cattle he concluded that solutions of sodium salts, particularly 
sodium bicarbonate, could effect closure of the groove in animals up 
to 2 yeare old.
The idea that metal salts could effect contraction of 
the reticular groove was perpetuated by Clunies Ross (1931, 1934) who 
found that sodium bicarbonate had little effect in sheep but that admin­
istration of solutions of copper salts, especially copper sulphate, 
regularly resulted in passage of liquids directly to the abomasum.
He thought that groove closure was a response to contact of the copper 
ions with buccal and pharyngeal mucous.mentranes, and reported thatthe 
solution when delivered to the oesophagus via a stoirach tube passed 
mainly to the reticulo-rumen. Clunies Ross (1931) also investigated 
the effects of starvation, and found that the withholding of food and 
water, particularly the latter, caused subsequently administered drenches 
to pass directly to the abomasum in most sheep. He further observed 
that where dye indicators were delivered to the abomasum, either by 
use of copper solutions or after starvation, they passed also, to a 
variable extent, into the small intestine.
Further work in sheep by Monnig and Quin (1935) and Watson 
and Jarrett (1941), and in cattle by Riek (1954) added support to the 
theory that chemical and/or mechanical stimulation of the mouth by 
solutions of metal salts was responsible for eliciting closure of the 
g-roove. Stimulation of pharyngeal receptors by the swallowing of 
fluids was shown to cause reflex contraction of the groove in
14
de-cerebrate calves by Comline and Titchen (1951),
Watson (1941) perfonned detailed studies of reticular groove 
function in larrtis and made the significant discovery that behavioural 
factors were of great inportance in initiation of the mechanism. He 
disproved earlier suggestions that factors such as the temperature 
(Trautmann and Schmitt, 1933), composition of the liquid (Wester, 1926) 
and posture assumed by the animal during drinking (Wise, Anderson 
and Miller, 1942) influenced the site of delivery of the liquid.
Watson found that provided the lambs were eager to suck or drink, 
the reticular groove closed and the liquid passed to the abomasim. As 
the desire to suck declined, more frequent passage to the forestomach 
was found to occur. The same author also observed that liquio taken 
merely in order to quench thirst, almost always passed entirely 
to the reticulo-rumen, even in lambs as young as 14-15 days old.
The introduction of intensive rearing methods stimulated 
more recent work on reticular groove function. In young fast-growing 
ruminants in which requirements for protein cannot be fully met by the 
supply of microbial protein, interest was aroused in the possibility 
of by-passing the rumen with high quality protein supplements which 
could be utilized more efficiently by the animal directly than via • 
microbial degradation.
drskov and Benzie (1969) re-examined the earlier work with 
salt solutions, but failed to demonstrate regular closure of the groove 
in adult sheep with suspensions of -protein v/ith or without added 
salt solutions, or with milk. They found, however, that in lambs 
trained to drink milk from a bottle or from, a trough protein suspension
15
could be later substituted for the milk and closure of the groove 
maintained even when the animals became adult. When the same 
suspensions were taken to quench thirst, however, they passed to the 
forestomach, thus confirm,ing the earlier observations by Watson 
(1941). The fact that the same suspensions could be taken by mouth 
and regularly have different destinations suggested to these authors 
that the stimulus to groove closure was not chemical or mechanical 
stimulation of the mouth or pharynx. They considered that it might 
be a conditioned reflex, and this possibility was subsequently tested 
(^rskov, Benzie and Kay, 1970). Catheters were inserted into lambs 
and suspensions of barium sulphate injected. When the animals were 
standing quietly at rest, the barium sulphate went to the forestomach.
If, however, the animal was shown the bottle or trough from which it 
was regularly fed, and the stockman associated with feeding, the 
barium sulphate passed to the abomasum. Feeding the liquid ad 
libitum to the lambs caused the reflex to disappear,
Lawlor, Hopkins and Kealy (1971) performed similar experiments 
with lambs, and discovered that in lambs which were slow to learn to 
suck or were reluctant to suck at all, milk more frequently passed to the 
reticulo-rumen than the abomasum.
The degree to which the reticular groove operates during 
administration of drugs by drenching and the possible effects of reticulo- 
ruminal by-pass are not well documented. Differences in plasma 
concentrations of drug following oral and intra-ruminal administration 
to adult cows have been observed, however, and were attributed to part 
of the oral dose being delivered directly to the abomasum (Aitken and 
Sanford, 1975), The differences at times later than two hours after
16
administration were not marked, and it is probable that the extent 
of by-pass was not great.
Circumstantial evidence for the occurrence of ruminai 
by-pass has come from studies with the flukicidal drug clioxanide 
which has been shown to be poorly effective in sheep when administered 
intra-abomasally [Boray end Roseby, 1969). These authors found that 
intra-ruminal administration of the drug was highly effective in all 
sheep, but that oral administration resulted in a wide variation in 
efficacy within the treated group, and they suggested that all or 
p art of the dose had passed via the reticular groove to the abomasum. 
By contrast a simdlar, more recent study with the sanro drug by 
Campbell and Brotowidjoyo (1975) showed similar efficacy of the drug 
when given by the oral and intra-ruminal routes although they also 
found a much reduced efficacy of the intra-abomasally administered 
dose.
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ABSORPTION FROM THE RUMEN
The stratified squamous epithelium which lines the ruminant 
forestomach is very different histologically from the generally 
accepted viev-j of what constitutes an absorptive surface. Whether 
the keratinized epithelium has developed simply as protection against 
the irritant nature of the ruminant diet, or v/hether part of its 
function is in fact to prevent the rapid, indiscriminate absorption 
of nutrients which may be detrimental to the microflora, which have 
their own requirement for nutrients, is speculative.
The histology of the rurran has been described by Barcroft, 
McAnally and Phillipson (1344). These authors found the keratinizeo 
layer of the epithelium bo be in many areas quite thin, and they also 
described the basal layer of the epithelium as being of columnar 
cells. Electron microscopy has shown the presence of intercellular 
pores (Hyden and Sperber, 1965) which it has been suggested may 
facilitate the absorption of some solutes. The papillae of the 
forestomach have an extensive underlying capillary network which may 
be of importance in the considerable absorption of volatile fatty 
acids which occurs from the reticulo-runon (Barcroft et al, 1944; 
Danielli, Hitchcock, Marshall and Phillipson, 1945), It has been 
shown that the areas of the rumen wall with large numbers of papillae 
absorb more VFA than areas with only small numbers of papillae 
(Aafjes, 1972) and that the development of ruminai papillae which 
occurs in the growing animal is necessary before appreciable 
absorption can occur (Sutton, McGilliard and Jacobson, 1963).
The mechanism of absorption of volatile fatty acids appears
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to be that of passive diffusion along a concentration gradient. Gray 
(1946) showed that the pH of the reticulo-ruminal contents has a 
marked effect on the rate of absorption, being much reduced at pH 
values of 7 and above. The theory of passive diffusion is also 
supported by the fact that if the contents of an isolated reticulo- 
rumen are replaced by solutions devoid of VFA, there is passage of 
VFA from the blood into the rumen to a final concentration approxi­
mating to that in plasma.
No evidence has been found for the existence of active 
transport mechanisms for the absorption of VFA despite numerous 
investigations. The same situation applies to arrmonia which may also 
be absorbed from the rumen (McDonald, 1948). Arrrrania itself has 
been shown to undergo more rapid absorption than the arrmonium ion 
(Hogan, 1961; Bloomfield, Kearley, Breach and Muhrer, 1963).
Active transport mechanisms do exist for the absorption 
of selected ionSg Sodium and, under certain conditions, chloride ions 
have been shown to be absorbed against both concentration and electro­
chemical gradients (Dobson, 1959). The same author found that the 
rumen wall is relatively impermeable to calcium, magnesium and phosphate 
ions.
The ability of the rumen to absorb drugs has been the subject 
of investigation by several workers. Trautmann (1933), one of the 
earliest investigators, by measuring rates of saliva production showed 
that pilocarpine and atropine were absorbed through the epithelium 
of an exteriorized cup of rumen mucosa. This was confirmed by Rankin 
(1940) who also demonstrated an increase in blood glucose concentration 
after administration of dextrose into a rumen pouch, and the presence
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of iodide in saliva after administration of potassium iodide into 
the tied-off reticule-rumen.
The same author showed that sufficient strychnine and 
sodium cyanide could be absorbed from the tied-off organ to kill a 
sheep within one hour of administration.
The effect of differences in pH on the rates of absorption 
of various sulfonamides, salicylic acid and p-toluidine was examined 
by Austin (1962). In his study, the reticulo-omasal orifice of 
atropinized and in some cases anaesthetized calves was obstructed 
with an inflatable balloon and the test drugs mixed with buffered 
solutions of various pH, which were placed in the washed out reticulo- 
rumen. Maintenance of the required pH was by the addition of IM 
HCl or NaOH. The change in concentration of the test drug relative 
to that of a non-absorbed volume indicator was then recorded at 
various intervals. In the experiments with salicylic acid, measurable 
blood concentrations of the drug were also reached.
The results showed that, in general, the drugs examined 
disappeared from the ruminai solution most rapidly at the pH values 
which favoured the existence of the unionized non-dissociated form. 
Sulfanilamide was the exception in having slower absorption from 
solutions of increasing acidity despite the fact that it is a weak 
acid. No satisfactory explanation for this paradox was found. The 
integrity of the ruminai epithelium was found to be largely destroyed 
after contact with the more alkaline of the solutions used in these 
experiments, and the effect of other solutions with pH values 
outwith the normal range of rumen contents on the permeability of 
the rumen to dr\jgs is unknown.
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A similar experimental model was used by Jenkins, Davis 
and Boulos (1975) in their studies on drug transfer across the 
ruminai wall of goats. These animals were in most cases conscious. 
Oesophageal and reticulo-omasal orifices were temporarily blocked 
and the washed out rumen filled with buffered Krebs Ringer phosphate 
solution at the desired pH. This fluid was continuously circulated 
extracorporeally by punp. The rate of disappearance of various 
drugs at different concentrations and at different pH values was then 
measured. The pH values used were less extreme than those used by 
Austin (1962), and mostly within the normal range of ruminai fluid. 
Diffusion of intravenously administered drugs into the reticulo- 
rumen from plasma under conditions of constant plasma concentration 
v/as also studied using this model.
These authors demonstrated that the rate of transfer of 
pentobarbitone, antipyrine, salicylate and quinine across the rumen 
wall was proportional to the imposed concentration gradient. Rates 
of disappearance were also pH dependent. Increasing the degree of 
ionisation of the drug by altering the pH of the surrounding medium 
lowered the rate of absorption. At pH values within the physiolo­
gical range normally encountered within the rumen, 75% absorption 
occurred after 2-4 hours or more. The authors suggested that the 
rate of mixing in the normal runen is very much slower then that 
provided by this model and therefore absorption is likely to be slower 
also, and that it would be unwise to deduce absolute figures from 
such a model.
All four drugs studied in these experiments were found in
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the rumen following intravenous infusion. Pentobarbitone and anti­
pyrine reached steady state concentrations close to those predicted 
from their pk^ values and the pH of the two compartments, but salicylate 
and quinine did not. Ruminai concentrations of salicylate were lower 
than those predicted, and those of quinine higher.
Ion trapping was also observed by these authors, _ Salicylate
failed to reach steady state concentration during infusion with an
alkaline ruminai solution over a ten hour period, the drug simply 
accumulating in the rumen. The same was true of quinine infused 
under conditions of an acidic ruminai solution.
These results agreed with earlier conclusions that passive 
diffusion was the mechanism of transfer of drugs between plasma and 
ruminai fluid. The poor agreement between observed and theoretical 
steady state ratios of salicylate was attributed to another mechanism 
of absorption for this drug, probably diffusion through aqueous pores. 
The reason for the similar findings with quinine was not apparent.
Further work in animals with surgically isolated rumen was
performed by McManus, Washko and Tocco (1966), again using goats.
These authors found slow absorption of thiabendazole to occur from the 
rumen after removal of most of the solid contents, but considered 
the process to be limited by the relatively low aqueous solubility 
of the drug at ruminai pH,
Diffusion of intravenously administered drug across the 
isolated rumen wall has been demonstrated for various sulfonamides, 
antipyrine and ephedrine (Corker and Stowe, 1967). These drugs 
were detected in ruminai fluid within ten minutes of intravenous
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injection. Tetracyclines were found not to distribute into the rumen.
These studies demonstrate that under certain conditions 
drug absorption through the rumen wall can occur, that the mechanism 
is almost certainly passive diffusion and that therefore the process 
is governed by the same factors - water/lipid solubility, degree of 
ionisation and concentration gradient that apply to passage of drugs 
across any biological membrane. They do not, however, assess the 
importance of this process in the normal intact animal where such 
factors as ruminai motility, the nature of the digesta or variations 
in ruminai blood flow which are known to occur may all influence 
absorption.
Studies in non-anaesthetized intact animals are relatively 
few, and the results are not always consistent with those in the 
experimental models referred to above. For example, Davis and 
Westfall (1972) found negligible concentrations of salicylate in the 
plasma of goats after administration of the sodium salt of the drug 
via a stomach tube and this they attributed to poor absorption of the 
drug. These authors used dose rates of up to 133 mg/kg which would 
have been expected to give rise to higher concentrations in the 
rumen than those used by Jenkins et al (1975) in their isolated rumen 
preparations, in which significant absorption was found to occur.
In cattle, however, the bio-availability of salicylate after 
oral administration of aspirin was found to be 70%, based on comparison 
of plasma concentrations after oral end intravenous administration 
(Gingerich, Baggot and Yeary, 1975) and it appears that there are 
species differences among ruminants as there are among monogastric
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animals.
Reports of direct comparative studies of drug absorption 
between ruminant and non-ruminant species in the literature are few. 
Those that there are have mostly been performed with the sulfonamide 
group of antibacterial drugs. Stableforth and Hignett (1942) found 
that absorption of orally administered sulfanilamide was slower in 
cows and in a sheep than in horses or dogs, and Stewart and Paris 
(1962) and Neumann (1964) found similar results with sulphamethoxy- 
pyridazine in their respective studies with cattle, horses and dogs, 
and cattle, dogs and pigs.
Although in these studies only plasma concentrations of the 
drug, which aro dependent on rates of distribution, metabolism and 
excretion as well as rate of absorption, were measured, the differences 
in the time taken to achieve maximum plasma concentrations in ruminât 
and non-ruminant species lead to the conclusion that absorption is 
generally slower in the ruminant.
The aims of the present study v/ere
1) to assess the role of the rumen as a possible site for drug 
absorption
2) to explore the possibility that weakly basic drugs accumulate 
in ruminai fluid by diffusion from the systemic compartment
3) to assess the influence of the reticular groove on the kinetics 
of orally administered drugs.
These aims VÆre to be achieved by studying the distribution of various 
weak acids and weak bases between plasma end the different parts of 
the gut after various routes of administration to sheep fitted with
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permanent ruminai, abomasal and duodenal cannulae.
CHAPTER 2 
MATERIALS AND METHODS
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ANIMALS
The sheep used during this study were Finn-Dorset cross females 
or castrated males, aged between 8 and 14 months at the beginning of 
the experiments. The sheep were fitted with permanent ruminai, abomasal 
and, in some cases, duodenal cannulae. They were kept indoors, fed
hay and water ad libitum and a conrmercial sheep concentrate ration was 
fed once daily.
CANNULAE
Rumen cannulae used initially were modified household sink 
waste fittings made of heavy inflexible plastic. These proved 
unsuccessful, and in two of the three sheep were rejected within 3 
months of insertion. Attempts were made to replace the original 
cannulae with ones of a flexible rubber type,* this was reasonably 
successful in one animal although there was persistent leakage around 
the barrel for several months.
It seemed probable that these early failures were due to 
the weight of the cannula and its flanges being too great for the 
body wall to support. Cannulae were therefore made to the same 
design but of a lighter weight Teflon material. None of these was 
rejected up to 2î years after insertion, and none of than leaked.
Abomasal and duodenal cannulae were of the same material, 
and were similarly well tolerated. The design and dimensions of 
the cannulae can be seen in Fig, 1 Cl). Fig. 1 (2) shov;s a 
ruminai cannula 1 year after insertion.
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F ig . 2 Cl) The design and dim ensions o f abomasa 1/duodenal 
and rum ina i cannulae
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r
F ig ' 2 C2] A rum ina i cannula one yea r a f t e r  in s e r t io n
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SURGERY
Animals were starved overnight before surgery. Anaesthesia 
was induced with intravenous sodium pentobarbitone (2G mg/kg) and 
maintained by incremental doses as required. Intubation was' carried 
out if there appeared to be any respiratory difficulty or likelihood 
of regurgitation of rumen contents, but generally this was not 
required.
Cannulae were fitted using standard surgical techniques 
[Meeker, 1974) and positioned as follows; ruminai cannulae in the 
posterior part of the dorsal sec, abomasal cannulae in the fundus 
of the abomasum and duodenal cannulae approximately 8 cm from the 
pylorus in the proximal part of the duodenum.
At least four weeks elapsed between ruminai and aborfesal/ 
duodenal cannulation in any animal. The same period was allowed 
before the animals were used for any experiments.
SAMPLING TECHNIQUES 
Blood sarrples
Blood samples were taken from the jugular vein using 
heparinised syringes (Monovettes, Sarstedt) and 20 gauge 1" needles. 
Rumen fluid
In the early experiments the animal was restrained on its 
right side. Rumen contents were then withdrawn, via the cannula, 
using a 10 ml syringe with one side of the barrel cut away to 
form a ladle. Later, to facilitate single handed sanpling, the 
animal was left standing during the procedure.
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Abomasal and duodenal fluid
Initially a blunt, soft plastic catheter (St. Peter's 
catheter) attached to a wide necked syringe was used to withdraw 
abomasal and duodenal fluid. This was discarded when it was 
found to be impossible to obtain repeat samples without causing 
haemorrhage into the gut. Instead a small beaker was held under 
the barrel of the cannula and samples obtained by normal passage of 
gut contents.
In all cases the first part of the sample was not collected 
as this portion may have been stationai-y in the barrel of the 
cannula and been unrepresentative of the contents.
TREATMENT OF SAMPLES
All samples were centrifuged at 1,000 x g for 10 minutes. 
The blood plasma was taken off from the red cells. Supernatant 
fluid from the gut samples was filtered (Whatman No. 4 filter 
paper). All samples were then deep frozen and stored at -20°C 
until assayed.
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ASSAY METHODS
MECLOFENAMATE
The concentrations of free, unconjugated meclofenarrate 
in plasma and gastro-intestinal fluid were measured by the 
spectrofluorirretric method of Glazko C19B6) with some minor 
modifications to the original method.
Total meclofenamate, comprising free meclofenamate, 
ester conjugates of meclofenamate, and also conjugated metabolites 
of meclofenamate can be measured using the same method after 
first freeing the conjugates by incubating with alkali at room 
tenrperature. This was not done as the metabolites are not 
differentiated from parent drug by this procedure and since 
neither they nor conjugated meclofenamate are biologically 
active, they were of less interest than the free drug.
REAGENTS
1) Sodium chloride Q.25M CAnalar)
2) Hydrochloric acid IM CAnalar)
3) Carbon tetrachloride (spectroscopic grade)
4) Trichloroacetic acid 50% w/v in carbon tetrachloride.
Procedure
To 1 ml of sample in a 15 ml ground glass stoppered 
test tube was added 5 ml of 0.25M sodium chloride solution. The 
pH was adjusted to 2 with 0.3 ml of IM hydrochloric acid, and 
5 ml of carbon tetrachloride added.
The tube was shaken for 10 minutes on a slow speed
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rotary mixer, and subsequently centrifuged at 1,000 x g for 
5 minutes,
3 ml of the organic layer was removed to a clean test 
tube and 4 drops of trichloroacetic acid solution (50% w/v in 
carbon tetrachloride] added. After 10 minutes the fluorescence 
was measured (360 nm excitation, 425 nm emission) on a Farrand 
Mark 1 fluorimeter.
Standards were prepared by adding known amounts of 
drug to blank plasma and gastro-intestinal fluid over a range 
of concentrations and taking these through the procedure.
Unknown samples were read from the calibration curve obtained 
from the standards.
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BENZIMIDAZOLES
Since fenbendazole was chosen as one of the drugs 
in this study, the method of Duwel, Hajdu and Dairm [1975) for 
its estimation in plasma was investigated. However this 
method using fluorescence spectrophotorretry was found to be 
unsuitable for a number of reasons.
Firstly, the fluorescence versus drug concentration 
plot became non linear at concentrations much lower than those 
which might be anticipated in the gut after normal doses.
Thus samples would have had to be diluted, possibly several 
times, to be read.
Secondly, blank plasma values obtained were high 
relative to the concentrations measured after recommended oral 
dosage.
Thirdly, it was found to be impossible to achieve 
consistent results from repeat samples, especially in the case 
of gastro-intestinal fluid.
In retrospect, it was fortunate that an alternative 
method was found as the metabolites of fenbendazole have a 
similar fluorescence and would not have been differentiated 
from the parent drug by this method.
Since the only other published work on fenbendazole 
was performed using radio-labelled drug (Christ, Kellner and 
Klopffer, 1974) which also does not differentiate parent drug 
from metabolites,it was decided to develop a chemical assay if 
possible. Gas-liquid chromatography (GLC) was considered
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briefly, but in view of the extremely low solubility of the drug 
in both water and organic solvents, and its low volatility, it 
was not surprising that no chromatographic peaks were obtained 
on a number of gas chromatographic columns (SE-3Ü; OV-17;
Carbowax] using maximum concentrations of fenbendazole in 
methanol.
High performance liquid chromatography (HPLC), a 
relatively new technique, has recently found a wide range of 
applications in the field of drug analysis and on theoretical 
grounds (low water and lipid solubility) was thought to be 
applicable to the benzimidazoles.
A nurrtjer of HPLC solvents were tried using an CDS 
Hypersil column. The solvents included various mixtures of 
methanol/water, methanol/anrmonium carbonate and methanol plus acid, 
It was found that satisfactory peaks were obtained with methanol/ 
arrmonium carbonate mixtures.
For the extraction of fenbendazole from body fluids 
several organic solvents were tried, including ether, hexane, 
ethylacetate, chloroform and dichloromethane. Each solvent 
was used to extract the drug from aqueous solutions of various 
pH values ranging from 6 to 10. Ether was found to be the most 
suitable solvent as it gave a good extraction and was evaporated 
rapidly at relatively low terrperatures. Fenbendazole v/as 
readily extracted at all the pH values used. Since fewer 
interfering peaks on the chromatograms arose from the use of a 
pH 7,4 phosphate buffer than with any other, this was the
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buffer chosen.
Under these extraction conditions, plasma and 
abomasal fluid gave chromatograms which were free of interfering 
peaks. Some interfering substances were occasionally found in 
rumen fluid extracts, and therefore a method for the cleaning up 
of rumen fluid samples was sought. Since benzimidazoles are 
basic drugs, standard methods for cleaning up basic drugs using 
a back extraction into dilute hydrochloric acid were tried. 
However it was found that unacceptably high losses occurred using 
these methods, and on further investigation it was found that 
the partition co-efficient of fenbendazole between ether and 
aqueous solutions so favoured the organic layer that acid 
extraction removed less than 15% of the drug from the organic 
layer.
Other methods for the clean up of ether extracts 
involved washing of the extract with various buffers and with 
hexane, but none of these significantly reduced the amount of 
contamination of the samples and wei"^  abandoned.
The following method for benzimidazole analysis was 
found to be highly satisfactory for plasma and abomasal fluid. 
The injection of lai"ge nurrbers of rumen samples did at times 
result in marked deterioration of column performance with loss 
of sensitivity and specificity. This necessitated cleaning and 
repacking of the top of the chromatographic column at intervals.
In addition, the large nimbers of contaminant peaks 
in rumen fluid sarrples on occasions gave rise to considerable
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difficulties in interpretation of chromatograms, particularly 
where low drug concentrations were being measured.
REAGENTS
All reagents were of analar grade,
13 Diethyl ether
2) Phosphate buffer pH 7.4 - 250 ml 0.2M potassium dihydrogen
phosphate + 197,5 ml 0.2M sodium hydroxide per litre
3) Methanol - redistilled before use
4) Arrmonium carbonate C0.05M) prepared using permanganate
distilled water.
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
Pump: Altex model 110
Detector: Cecil CE 2012 variable wavelength UV spectro­
photometer
Column: 100 rrm x 8 rrm Shandon Southern (prepacked]
Packing; DOS Hypersil 10
Wavelength: 292 nm
Absorbance: 0,1 A.U.F.S.
Solvent: Methanol; Ammonium carbonate 60:20
Flow rate; 1.5 ml/min
Under these conditions fenbendazole had a retention time of 4.2 
minutes.
Procedure
To 4 ml of plasma or gastro-intestinal fluid in a 
50 ml ground glass stoppered tube was added 4 ml of pH 7.4
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phosphate buffer, and 20 ml of diethyl ether. The tube
was stoppered and shaken for 10 minutes on a slow rotary/ mixer.
IB ml of the ether Cupper) layer was removed to a 50 ml glass 
test tube using a 5 ml adjustable pipette. [The pipette tip 
required to be pre-wetted with the ether before accurate transfer 
could be effected). A further 20 ml of ether was added to the
first tube and shaken as before. 20 ml of the ether was
removed and combined with the first 16 ml. The ether was slowly 
evaporated on a dri-bath at 55°C under nitrogen to an approximate 
volume of 6 ml, and transferred to a conical 10 ml glass tube.
The 50 ml tube was rinsed three times with 1 ml of ether and 
the washings added to the 10 ml tube each time. The ether 
was evaporated to dryness, the walls of the tube rinsed down 
with 0.5 ml of ether and this again evaporated to dryness.
The residue was redissolved in an appropriate 
volume (50 yl for plasma samples) of methanol by tilting and 
rotating the tube in an ultrasonic bath. 5 yl of this extract 
was used for HPLC analysis.
The concentration of fenbendazole in the samples was 
calculated with the aid of calibration curves prepared by 
adding known amounts of fenbendazole to blank plasma or gastro­
intestinal fluid to give an appropriate concentration range.
These standards were extracted along with the samples each time 
and the peak height of fenbendazole in the samples compared with 
the calibration curve obtained.
Non-extracted standard solutions of fenbendazole in
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methanol were also injected as a check on the performance on the 
column, and to estimate recoveries of the drug.
The same method was found to be applicable to all the 
benzimidazoles studied and Fig, 2 (3) shows a chromatogram of eight 
of the benzimidazoles. The methanol:ammonium carbonate ratio of 
the solvent can be adjusted as shown in Table 2 (1) to produce 
more practical retention times for any particular drug.
The method is sufficiently sensitive to measure plasma 
and gastro-intestinal fluid concentrations down to 0.02pg/ml.
The accuracy and precision of the method was determined 
for each drug by adding known amounts of the drug to blank plasma 
and abomasal fluid. Samples of each known concentration were then 
assayed in triplicate (Table 2 (2)).
It was determined that the recovery losses were due to 
the extraction procedure rather than to benzimidazole degradation.
Recoveries for fenbendazole, oxfendazole and albendazole 
from plasma, abomasal fluid and ruminai fluid after allowing for 
the losses due to discarded solvent are shown in Table 2 (3).
Typical high perfonrance liquid chromatograms for 
oxfendazole extracted from the body fluids using the method 
are shoivn in Fig. 2 (4).
SEPARATION AN'D ID&NTIFICATION OF METABOLITES
Under the solvent system described above, the respective 
major metabolites of both fenbendazole (i.e. oxfendazole and 
oxfendazole sulfone Fig. 5 (2). and albendazole (i.e. albendazole 
sulfoxide, albendazole sulfone and albendazole-2-aminosulfone
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Fig. 2 (3) High performance liquid chroiratogram of oxfendazole (1), 
thiabendazole (2), cambendazole (3), mebendazole (4), 
oxibendazole (5), albendazole CB), fenbendazole (7) and 
parbendazole (8) using methanol: ammonium carbonate 
(0,005 M) B5;35. Five microlitres of a solution 
containing 10 yg/ml of each benzimidazole in methanol 
was used for injection
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TABLE 2 Cl) RETENTION TIMES OF EEiNZIMIDAZOLES USING VARIOUS RATIOS 
OF METHANOL:AMMONIUM CARBONATE AS ELUTING SOLVENT FOR 
HPLC
Benzimidazole
Retention
Times
Methanol : Ammonium Carbonate (0.05M) Cmins)
Thiabendazole
Cambendazole
Parbendazole
Oxibendazole
Mebendazole
Fenbendazole
Oxfendazole
Albendazole
65 : 35
70 Î 30
85 ; 15
75
75
80
75
75
25
25
20
25
25
4.1
4.7 
3.6
3.8 
4.4
4.2
3.8
4.2
40
TABLE 2 C20 ESTIMATION OF EENZIMIDAZÜLES IN PLASMA AND AEOMASAL FLUID
Fenbendazole 
added to 
Plasma 
Cyg)
Fenbendazole
Measured
tyg) Mean + S.E.M.
S.E, as 
% of 
Mean
Ratio 
Assayed 
to Added
0.2 0.16 0.16 0.15 0.16 ± 0.003 2.1 0.80
0.4 0.30 0.32 0.28 0.30 + 0.01 .3.6" 0.75
0.8 0.69 0.61 0.65 0.65 ± 0.02 3.6 0.81
1.5 1.21 1.19 1.30 1.23 ± 0.03 2.8 0.82
Albendazole 
added to 
Abomasa1 
Fluid tyg)
Albendazole
Measured
Cvs) Mean ± S.E.M.
S.E, as 
% of 
Mean
Ratio 
Assayed 
to Added
1.0 0.86 0.90 0.89 0.88 ± 0.01 1.37 0.88
2.0 1,60 1.75 1.73 1.69 ± 0.05 2.8 0.65
4.0 3.20 3.36 3.45 3.34 ± 0.07 2.2 0.84
10.□ 8.34 9.57 8.72 8.68 ± 0.36 4.1 0.69
□xfendazole 
added to 
Abomasa1 
Fluid Cyg)
Oxfendazole
Measured
Cyg) Mean + S.E.M.
S.E.
% of 
Mean
Ratio 
Assayed 
to Added
1.5 1.03 1.08 1.13 1.08 ± 0.03 2.7 0.72
7.5 5.90 6.20 6.10 6.07 ± 0.09 1.5 0.61
15 12.10 11.20 11.40 11.57 + 0.27 2.4 0.77
30 24.50 24.20 26.10 24.93 i 0.59 2.4 0.83
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TABLE 2 C3) PERCENTAGE RECOVERY OF BENZIMIDAZOLES ESTIMATED BY 
ADDING KNOWN AMOUNTS OF DRUG TO BLANK PLASMA AND 
GASTRO-INTESTINAL FLUID AND TAKING SAMPLES THROUGH 
THE ANALYTICAL PROCEDURE
Benzimidazole
%
Plasma
Recovery
Ruminai Fluid Abomasal Fluid
Fenbendazole 83-100 Cn=15) 82-105 (n=12] 83-112 Cn-12)
Oxfendazole 70- 97 (n=10) 70- 96 Cn=103 72- 92 (n=12)
Albendazole 73-103 (n=10) 72- 97 (n-10) 77- 94 Cn=10)
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Fig. 2 C4) High performance liquid chromatograms of samples
from a sheep dosed with oxfendazole 10 mg/kg 
Key a) plasma before oxfendazole administration
b) plasma estimated to contain 0,16 yg/mi oxfendazole
c) abomasal fluid estimated to contain 0,25 yg/ml
oxfendazole
d) ruminai fluid estimated to contain 0.25 yg/ml
oxfendazole
e) oxfendazole standard in methanol (10 yg/ml)
<ir
- Û
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Fig. 5 [0)} appeared as single chromatographic peaks. These 
peaks were well separated from that of the parent compound, 
having a much shorter retention time in both cases.
The two important metabolites [vide infra), the 
sulfoxide and sulfone, could not be separated using any variation 
of the methanol/ammonium carbonate solvent and a different solvent 
v;as necessary. It was found that methanol/water [in the same 
ratio as the methanol/ammonium carbonate mixture used for 
estimation of the parent drug) with the addition of a small 
amount of acid [1 yl of 1.1% w/v perchloric acid per ml of 
solvent) resulted in separation of the two compounds. Under 
these conditions the retention times of the sulfone metabolites 
were unchanged whilst those of the sulfoxides were increased.
Albendazole-2-aminosulfone, albendazole and fenbendazole 
were not detected under this system. [The equivalent 2-amino 
sulfone metabolite of fenbendazole was not available to us).
Albendazole-2-amino sulfone was separable from the 
other two metabolites of albendazole by using a 50:50 methanol: 
arrrmnium carbonate solvent, and under these conditions eluted 
in advance of the sulfoxide and sulfone.
Fig. 2 (5) shows high performance liquid chromatograms 
of albendazole and its metabolites in abomasal fluid using 
methanol/ammnium carbonate, and Fig, 2 [6) shows separation of 
the sulfoxide and sulfone using methanol/perchloric acid.
The shape of the sulfoxide peak using the methanol/ 
perchloric acid solvent was somewhat broader and flatter than
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Fig. 2 (5) High performance liquid chromatogram of albendazole 
and its metabolites in abomasal fluid using methanol 
ammonium carbonate
a) abomasal fluid extract before drug administration
b) extract containing albendazole + metabolites
c) albendazole 10 yg/ml in methanol
d) albendazole sulfoxide 10 yg/ml in methanol
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Fig. 2 (6) Separation of albendazole sulfoxide and albendazole 
sulfone using methanol/perchloric acid
a) sulfone 20 yg/ml in methanol
b) sulfoxice 50 yg/ml in methanol
c) abomasal fluid extract containing 0.95 yg/ml
sulfoxide and 0.33 yg/ml sulfone
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that of the same compound under methanol/amrronium carbonate.
This resulted in reduced sensitivity of the method, and the limit 
of detection of sulfoxide was increased from 0.01 yg/ml under 
methanol/arrmonium carbonate to 0,1 yg/ml. That of the sulfone 
under both solvents was 0,01 yg/ml,
LEVAMISOLE
Levamisole has been determined in bovine tissues and 
milk by cathode ray polarography (Holbrook and Scales, 1967} and 
in milk by gas-liquid chromatography (Smith, Pasarela and 
Wycroff, 1976}. Cathode ray polarography, as well as being 
unavailable in this department, was known to be a relatively 
insensitive technique. The gas chromatographic method involved 
a lengthy clean up procedure, and it was thought that high 
performance liquid chromatography might well provide a more suitable 
technique for the analysis of levamisole. The HPEC solvents and 
ether extraction used for benzimidazole analysis v/ere found to be
equally suitable for levamisole and the following method was
derived.
REAGENTS
All reagents were of analar grade.
1} Diethyl ether 
2} Borate buffer pH 9
Solution A - Dissolve 0.746 g potassium chloride end
0,516 g boric acid in 180 ml of distilled
water.
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Solution B - 0.2N sodium hydroxide.
Mix solutions A and B in the approximate proportion of 9:1 to give 
pH 9 CpH meter].
3) Methanol - re-distilled before use
4) Ammonium carbonate (0.05M) prepared using permanganate
distilled water
5) Britton Robinson buffer pH 10,7
Solution A - 11.3 ml glacial acetic acid 3
13.55 ml phosphoric acid CS.G, 1.73
3 litre
12,45 g boric acid )
Solution B - IM sodium hydroxide.
Mix solutions A and B in approximate proportions 5:4 to give 
pH 10.7 CpH meter}.
6 3 O.IM hydrochloric acid 
7} IM sodium hydroxide.
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
Pump: Altex model 110
Detector: Cecil CE 2012 variable wavelength spectrophoto­
meter
Column; 100 rrm x 5 nrn Shandon Southern
Packing: DOS Hypersil 10 (Whatman} '
Wavelength: 220 nm
Absorbance 0.1 A.Ü.F.S.
Solvent: Methanol:ammonium carbonate 65:35
Flow rate; 1.0 ml/min.
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Under these conditions levamisole had a retention time of 2.7 
minutes.
Procedure for plasma
To 2 ml of plasma in a 50 ml ground glass stoppered test
tube v;as added 2 ml of pH 9 borate buffer and 15 ml of ether.
The tube was firmly stoppered and shaken for 10 minutes on a slow 
rotary mixer. 10.5 ml of the ether Cupper) layer was removed
to a 50 ml test tube using a 5 ml adjustable'pipette. [The
pipette tip required to be pre-wetted with the ether before
accurate transfer could be effected).
A further 15 ml of ether was added to the first tube
and shaken as before for 10 minutes. 15 ml of the ether (upper)
layer was transferred to the second test tube, and the combined ether 
evaporated on a dri-bath at 55°C under nitrogen to a volume of 
approximately 6 ml. This was transferred to a 10 ml conical 
glass tube. The 50 ml test tube was washed down three tines 
with 1 ml of ether and the washings added each time to the 10 ml 
tube. This was evaporated to dryness, the walls washed with 
0.5 ml of ether and again evaporated to dryness. The residue 
was taken up in 100 pi of methanol by rotating and tilting the 
tube in an ultrasonic bath. 5 yl of the extract was injected on 
to the HPLC colum.
Procedure for abomasal and ruminai fluid
Abomasal fluid is strongly acidic (generally pH between 
2,2 and 2,8 in these sheep) and levamisole, in contrast to 
fenbendazole, was well extracted into ether at alkaline pH only.
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Since the addition of 2 ml of pH 9 borate buffer as used in the 
method for plasma raised the pH to only 7, it was found necessary 
to substitute a pH 10.7 Britton-Robinson buffer. This gave a 
satisfactory extraction, using the above procedure.
Rumen samples gave rise to many interfering peaks on 
the chromatograms and so a clean up step was found to be necessary 
as described below.
The sample was buffered and shaken twice with ether as for 
plasma. The ether layers were transferred to a 50 ml ground glass 
stoppered tube and shaken for 10 minutes with 3 ml of hydrochloric 
acid. The ether [upper) layer was discarded using suction, taking 
care not to disturb the interface. A further 15 ml of ether was 
added to the aqueous layer followed by 0.5 ml of sodium hydroxide.
This was shaken for 10 minutes as above. 12 ml of the ether (upper) 
layer was removed to a 50 ml glass test tube, A further 15 ml of 
ether was added to the aqueous layer and shaken for 10 miinutes as 
above. 15 ml of the ether (upper) layer was removed and contiined 
with the 12 ml of ether. The cormined ether was treated as described 
for plasma.
This back extraction into acid followed by a second 
forward extraction resulted in residues with negligible interfering 
s ubstances.
The concentration of levamisole in the samples was 
calculated from calibration curves prepared by adding kno'^ /n 
amounts of levamisole to blank plasma or gastro-intestinal fluid 
to give a reasonable concentration range, viz 0.2-3.0 yg/ml for plasma.
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These standards v/ere extracted along with the samples 
and the peak height of the sample compared with the calibration 
curve prepared from the standards.
Non-extracted standards of levamisole in methanol 
were also injected as a check on the column performance, and to 
estimate recoveries of levamisole using this procedure.
Typical chromatograms of levamisole are shovm in 
Fig. 2 (7). Recoveries were as follows:
Plasma 68% [81-98) n = 30
Abomasal fluid 85% [76-96) n “ 28
Ruminai fluid 80% (74-69) n = 25.
The precision and accuraoy of the method were determined by 
adding known amounts of levamisole to plasma. Samples of each 
known concentration were then assayed in triplicate by both 
procedures. The results are shown in Table 2 (4).
It was determined that recovery losses v/ere due to 
extraction losses rather than to degradation of the levamisole.
51
Fig, 2 C7) High performance liquid chromatograms of levamisole 
in ræthanol and in extracts of samples from a sheep
dosed with levamisole 7.5 mg/kg
a) 5 microlitres of 5 yg/ml levamisole in methanol
b) 5 microlitres of 10 yg/ml levamisole in methanol
c) 5 microlitres of 15 yg/ml levamisole in methanol
d) 5 microlitres of 20 yg/ml levamisole in methanol
e) plasma before levamisole administration
f) plasma estimated to contain 0.42 yg/ml levamisole
g) ruminai fluid before levamisole administration
h) ruminai fluid estimated to contain 0.36 yg/ml
levamisole
LU
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TABLE 2 C4) ESTIMATION OF LEVAMISOLE IN FLASMiA
Levamisole
Added
(pg)
Levamisole
Measured
Cug) Mean + S.E.M.
S.E. as 
% of 
Mean
Ratio of 
Assayed to 
Added
0.4 0.32 0.32 0.30* 0.31 ± 0.007 2.2 77.5
0,30 0.27 0.29*^ 0.29 + 0.009 3.0 72.5
1.0 0.82 0.78 0.64* 0.61 i 0.02 2.2 0.81
0.78 0.77 0.74*^ ' 0.76 ± 0.01 1.6 0.76
1.5 1.26 1.40 1.29* 1.32 ± 0.04 3.2 0,88
1.26 1.15 1.19"^ 1.2Ù ± 0.03 2.7 0.80
2.0 1.60 1.56 1.68* 1.61 ± 0.04 2.2 0.81
1.61 1.50 1.53*^ 1.55 + 0.03 2.1 0.78
* Short procedure 
t Using back extraction.
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STATISTICS
Conventional statistical rrethods were used for calculating 
means Cx) and standard error of the mean [S.E.M.)
Intra-individual differences were tested for significance 
using Student’s ’t’ test for paired samples (Snedecor, 1956)
Areas under the curve were calculated using Simpson's 
approximation (discrete).
CHAPTER 3 
STUDIES WITH MECLOPENAMATE
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Neclofenamic- acid is a non-steroidal anti-inflarrmatory drug 
which has been shown to possess anti-anaphylactic activity in cattle 
(Aitken and Sanford, 1969, 1972; Wells, Eyre and Lumsden, 1973) and 
in sheep (Alexander, Eyre, Head and Sanford, 1970). It is marketed 
for use in horses in the United Kingdom ("Arquel", Parke-Davis).
The structure of meclofenamic acid is shown in Fig. 2 (1), 
Meclofenamic acid was used in this study as an acidic drug 
for which a simple, sensitive assay procedure was available.
Plasma concentrations of meclofenamate in cattle after 
intravenous, oral and intra-ruminal administration have been reported 
by Aitken and Sanford (1975), These authors found maximum 
concentrations in plasma occurring at 30 minutes and at 4-5 hours 
after oral dosing of both adult cattle and 4-6 month old calves. 
After intra-ruminal administration to tv/o cows, a single plasma peak 
occurred at 8-12 hours.
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Fig. 3 Cl) The structure of meclofenamic acid
/
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EXPERIMENTS WITH MECLOFENAMIC ACID
Meclofenamic acid granules ("Arquel”, Parke-Davis) were 
administered to three sheep as follows:
Experiment 1) Orally as a slurry in 150 ml of water using a
drenching bottle. The dcse rate was 20 mg/kg. 
Experiment 2) Intra-ruminally via the ruminai cannulae at a dose 
rate of 20 mg/kg.
Experiment 3) Intra-abomasally via the abomasal cannulae at a 
dose rate of 10 mg/kg.
Blood and ruminai aborasal and duodenal fluid samples were
taken prior to drug administration and at 10, 20 and 40 minutes and 1,
15, 2, 3, 5, 7, 10, 14, 16 and 22 hours after administration.
Samples were taken and treated as described in Chapter 2.
They were later analysed as described in Chapter 2 for the concentration 
of free meclofenamate.
RESULTS
The mean plasma and gastro-intestinal fluid concentrations 
of meclofenamate in the three sheep after oral, intra-ruminal and intra- 
abomasal administration are shown in Figs. 3 (2), 3 (3) and 3 (4) 
respectively and in Tables 3 (1) to 3 (12).
In all sheep after oral administration a bi-phasic pattern 
in plasma concentrations was observed; an initial maximum occurring 
within 40 minutes of drug administration and a second more sustained 
peak about 5 hours after administration.
After intra-ruminal administration the initial maximum
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Fig. 3 (2) Mean plasma and gastro-intestinal fluid concentrations 
(pg/ml) of meclofenamate in three sheep after oral 
administration of meclofenamic acid (20 mg/kg)
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Fig. 3 (3) Mean plasma and gastro-intestinal fluid concentrations 
(yg/ml) of meclofenamate in three sheep after intra- 
ruminal administration of rreclofenamic acid (20 mg/kg)
~o
o
'cmV4-
*T3
Q.
o
—LD
—0
O
CO
( | U j / 6 r l )  UOIjDJjUODUOD 04D LU D U 0jO |D 9V7
59
Fig, 3 C43 Mean plasma and gastro-intestinal fluid concentrations 
(yg/ml of meclofenamate in three sheep after intra- 
abomasal administration of meclofenamic acid (10 mg/kg3
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TABLE 3 Cl) PLASMA CONCENTRATIONS Cyg/ml) OF MECLOFENAMATE AFTER
ORAL ADMINISTRATION OF MECLOFENAMIC ACID TO 3 SrEEP
C20 rr,g/kg)
Time
S h e e p  n u m b e r
71 74 75 Mean ± S.E.M,
10 min 3.33 1.96 1.95 2,42 ± 0.46
20 min 4.89 3.01 2.64 3.51 ± 0.70
40 min 4.89 3.48 5.02 4.46 ± 0.49
1 hr 4.07 2.81 4.8D 3.89 ± 0.58
1| hr 3.31 2.65 5.25 3.74 ± 0.76
2 hr • 3.82 2.54 5.71 4.02 ± 0.92
3 hr 6.15 2.98 6.68 5.27 ± 1.15
5 hr 9.32 3.25 5.45 6.01 ± 1.78
7 hr 8.06 3.60 4.96 5.54 ± 1.32
10 hr 5.53 1.43 2.07 3.01 ± 1.27
14 hr 2.24 1.11 1.07 1.47 ± 0.38
18 hr 1.35 0.41 0.66 0.81 ± 0.26
22 hr 0.64 0.41 0.29 0.45 ± 0.10
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TABLE 3 C2) RUMINAL FLUID CONCENTRATION Cyg/rni) DF MECLOFENAMATE
AFTER ORAL ADMINISTRATION OF MECLOFENAMIC ACID TO
3 SHEEP C20 mg/kg)
Time
S h
71
e e p  n u m [ 
74
] e r
75 Mean ± S.E.M.
10 min 0.81 4.17 0.16 1.71 ± 1.24
20 min 1.42 3.78 0.24 1.81 ± 1.04
40 min . 2.61 5.49 0.38 2.83 ± 1.48
1 hr 2.95 4.07 0.41 2.48 ± 1.08
li hr 6,10 4,60 0.36 3.69 ± 1.72
2 hr 2.81 5.54 0.33 2.89 ± 1.50
3 hr 2.98 4.65 0.48 2.71 ± 1.21
5 hr 2.64 3.73 0.13 2.17 ± 1.07
7 hr 1.64 2.32 0.08 1.35 ± 0.66
10 hr 0.38 0.40 0.04 0.27 ± 0.12
14 hr 0.18 0.05 0 0.08 ± 0.05
16 hr 0.11 0.01 0 0.04 ± 0.04
22 hr 0 0 0 0
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TABLE 3 C3) ABOMAEAL FLUID CONCENTRATION Cyg/ml] OF MECLOFENAMATE
AFTER ORAL ADMINISTRATION OF MECLOFENAMIC ACID TO
3 SHEEP C2G mg/kg)
S h e e p n u m b e r
Time 71 74 75 Mean ± S.E.M.
10 min 3.67 0.84 8.41 4.37 ± 2.20
20 min 7.78 1.46 2.34 3.86 ± 1.98
40 min 4.69 0.94 1.90 2,51 + 1.12
1 hr 2.91 1.03 1.22 1.72 ± 0.60
U  hr 0.41 0.90 1.44 0,92 ± 0.30
2 hr 3.69 0.79 1.67 2.05 ± 0,66
3 hr 1.90 1.46 1.10 1.49 ± 0.23
5 hr 1.00 1.55 0.76 1.10 ± 0.22
7 hr 1.41 0.92 0.17 0.83 ± 0.34
10 hr 2.20 0.31 0.10 0.87 ± 0.66
14 hr 0 0.14 0.01 0.05 ± 0.05
18 hr 0 0 0 0
22 hr 0 0 0 0
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TABLE 3 C4) DUODENAL FLUID CONCENTRATION Cyg/ml) OF MECLOFENAMATE 
AFTER ORAL ADMINISTRATION OF MECLOFENAMIC ACID TO 
3 SHEEP (20 mg/kg)
T ime
S h e e n  n u m b e r
71 74 75 Mean ± S.E.M.
10 min 3.47 0.76 1.65 1.96 ± 0.80
20 min 4.98 0.72 1.19 2.30 ± 1.35
40 min 3.22 1.92 2.75 2.63 ± 0.38
1 hr 2.55 3.14 1,59 2,43 ± 0.45
U  hr 1.63 2.25 1.26 1.72 ± 0.28
2 hr 1.77 1.39 0.98 1,38 ± 0,23
3 hr 2.70 0.95 0,76 1.47 ± 0.62
5 hr 4.68 1.11 0,55 2.11 ± 1,29
7 hr 2.44 1.15 0,03 1.21 ± 0.70
10 hr 0.61 0.54 0,52 0.56 ± 0.03
14 hr 0.14 0.19 0.07 0.13 ± 0.03
18 hr 0 0.35 0,09 0.15 ± 0.10
22 hr 0.09 0,05 0 0.05 ± 0.02
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TABLE 3 (5) PLASMA CONCENTRATIONS Cyg/ml) OF MECLOFENAMATE AFTER
INTRA-RUMII'iAL ADMINISTRATION OF MECLOFENAMIC ACID TO
3 SHEEP (20 mcr/ka)
S h e e p n u m b e r
Time 71 74 75 Mean ±: S.E.M.
10 min 0 0.20 0.45 0.22 ± 0.13
20 min 0.08 0.33 0.68 0.36 ± 0.17
40 min 0.54 0.53 0.68 0.58 ± 0,05
1 hr 1.98 2.35 0.65 1.56 ± 0.52
1| hr 2.65 2.55 0.64 2.01 ± 0,69
2 hr 3.36 2.75 1.90 2.67 ± 0.42
3 hr 3.69 2.39 2.47 2.85 ± 0.42
5 hr 4.65 3.84 3.80 4.10 ± 0.28
7 hr 4.98 3.47 2.98 3.81 ± 0.60
10 hr 3.00 1.91 2.40 2.44 ± 0.32
14 hr 2.21 1.08 1.30 1.53 ± 0,35
18 hr 1.18 0.53 1.20 0.97 ± 0.22
22 hr 0.49 0.26 0,65 0.47 ± 0.11
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TABLE 3 (6) RUMINAL FLUID CONCENTRATION (yg/ml) OF MECLOFENAMATE
AFTER INTRA-RUMINAL ADMINISTRATION OF MECLOFENAMIC
ACID TO 3 SHEEP (20 mg/kg)
S h e e p n u m b e r
Time 71 74 75 Mean ± S.E.M.
10 min 2.47 4.69 2.57 3.24 ± 0.72
20 min 4.66 3.96 4.85 4.49 ± 0.27
40 min 2.06 6.32 3.38 3.93 ± 1.25
1 hr 2.14 3.49 5.71 3.78 ± 1.04
I5 hr 2.28 4.44 5,58 4.10 ± 0.97
2 hr 3.04 4.14 3.29 3.49 ± 0.33
3 hr 4.58 5.30 2.89 4.26 ± 0.71
5 hr 5,58 2.54 2.65 3,59 ± 1.00
7 hr 3.65 2.80 1.71 2.72 ± 0.56
10 hr 2.25 1.16 1.05 1,49 ± 0.38
14 hr 0.64 0.30 0.44 0.46 ± 0.10
IB hr 0.28 0.10 0.25 0,21 ± 0.06
22 hr 0.15 0 0.08 0.08 ± 0.04
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TABLE 3 (7) ABOMASAL FLUID CONCENTRATIDi 
AFTER INTRA-RUMINAL AuMINIS 
ACID TO 3 SHEEP (20 mg/kg)
N (yg/ml) 
TRATION OF
OF MECLOFENATATE 
MECLOFENAMIC
S h e e p  n u m h e r
Time 71 74 75 Mean ± S.E.M,
10 min D.Ol 0 0 0
20 min 0 0 0 0
40 min 0 0.02 0 0.01 ± 0.01
1 hr 0 0 0 0
lA hr 0 0,07 0 0,02 ± 0.02
2 hr 0.05 0,21 0.04 0.10 ± 0,06
3 hr 0.16 0.20 0.22 0.19 ± 0,02
5 hr 0.18 0.23 0.16 0.19 ± 0.02
7 hr 0.26 0.18 0.03 0,16 ± 0.07
10 hr 0.15 0.03 0.04 0.07 ± 0.04
14 hr 0.07 0.06 0 0.04 ± 0,02
18 hr 0 0 0.02 0.01 ± 0.01
22 hr 0 0 0 0
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TABLE 3 (8) DUODENAL FLUID CONCENTRATION Cyg/ml) OF MECLOFENAMATE
AFTER INTRA-RUMINAL ADMINISTRATION OF MECLOFENAMIC
ACID TO 3 SHEEP C20 mg/kg)
Time
S h e e p n u m b e r
71 74 75 Mean ± S.E.M.
10 min 0 0 0 0
20 min 0 0 0 0
40 min 0 0 0 0
1 hr 0 0 0 0
Ig hr 0.02 0.08 0 0.03 ± 0.02
2 hr 0.01 0.12 0 0.04 ± 0.04
3 hr 0.22 0.15 0.14 0.17 ± 0.03
5 hr 0.13 0.12 0.11 0.12 ± 0.01
7 hr 0.15 0.05 0,09 0,10 ± 0.03
10 hr 0.11 0 0.02 0.04 ± 0.03
14 hr 0 0 0.01 0
18 hr 0 0 0 0
22 hr 0 0 0 0
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TABLE 3 [9} PLASMA CONCENTRATION Cye/rnl) OF MECLOFENAMATE AFTER 
INTRA-AEOMASAL ADMINISTRATION OF MECLOFENAMIC ACID
TO 3 SHEEP (10 mg/kg)
S h e e D n u m b e r
Tims 71 74 75 Mean ± S.E.M.
10 min 0.55 0.07 0,34 0.32 ± 0.14
20 min 1.46 0.06 0.57 0.70 ± 0.41
40 min 2.32 0.42 0.74 1.15 ± 0.59
1 hr 1.80 0.98 0.68 1.15 ± 0.33
li hr 1.66 1.06 1,24 1.32 ± 0.18
2 hr 1,56 1.13 1.80 1.50 ± 0.20
3 hr 0.96 1,26 1.43 1.22 ± 0.14
5 hr 0.60 0.84 0.80 0.75 ± 0.07
7 hr 0.30 0.37 0.46 0.38 ± 0.05
10 hr 0.15 0,19 0.29 0.21 ± 0.04
24 hr 0.01 0.01 0.03 0.02 ± 0.01
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TABLE 3 (10) RUMINAL FLUID CONCENTRATION (pg/ml) OF MECLOFENAMATE 
AFTER INTRA-ABOMASAL ADMINISTRATION OF MECLOFENAMIC 
ACID TO 3 SHEEP tlü mg/kg)
Time
S h e e p n u m b e r
Mean ± S.E.M.71 74 75
10 min 0.06 0 0.05 0.04 ± 0.02
20 min 0.01 0 0.02 0.01 ± 0.01
40 min 0.24 0.19 0.08 0.17 ± 0.05
1 hr 0 0 0.07 0.02 ± 0.02
1& hr 0 0 0.03 0.01 ± 0.01
2 hr 0 0 0.03 0.01 ± 0.01
3 hr 0 0 0.04 0.01 ± 0.01
5 hr 0 0.02 0 0.01 ± 0.01
7 hr 0 0 0 0
10 hr 0 0 0 0
24 hr 0 0 0 0
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TABLE 3 (11) ABOMASAL FLUID CONCENTRATION (yg/ml) OF MECLOFENAMATE 
AFTER INTRA-AEOMASAL ADMINISTRATION OF MECLOFENAMIC 
ACID TO 3 SHEEP dC mg/kg)
Tims
S h e e p n u m b e r
NE.M.71 74 75 Mean ± S
10 min 2,26 3.37 0.48 2.03 ± 0.65
20 min 0.95 7.70 0.51 3.05 ± 2.33
40 min 0.82 1.58 0.55 0.98 ± 0.31
1 hr 0.23 0.47 0.55 0.42 ± 0.10
Is hr 0.87 0,33 0.11 0.44 ± 0.23
2 hr 0.24 0.30 0.16 0.23 ± 0.04
3 hr 0.01 0.11 0.21 0.11 ± 0.06
5 hr 0 0.07 0.02 0.03 ± 0.02
7 hr 0 0 0 0
10 hr 0 0 0 0
24 hr 0 0 0 0
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TABLE 3 (12) DUODENAL FLUID CONCENTRATION (pg/ml) OF MECLOFENAMATE 
AFTER INTRA-ABOMASAL ADMINISTRATION OF MECLOFENAMIC 
ACID TO 3 SHEEP (10 mg/kg)
S h e e p  n u m b e r
Time 71 74 75 Mean ± S.E.M,
10 min 0.36 0.02 0.69 0.36 ± 0.19
20 min 1,03 0,55 0.44 0.67 ± 0.18
40 min 1.38 0.34 0.84 0.85 ± 0.30
1 hr 2.41 0.26 0.59 1.09 ± 0.67
11 hr 1.23 0.35 0.41 0.66 ± 0.26
2 hr 1,12 0.20 No S 0.66 ± 0.46
3 hr 0.33 0.06 No S 0.20 ± 0.14
5 hr 0,08 0 0.50 0.19 ± 0.16
7 hr 0.02 0 0 0.01 ± 0.01
10 hr 0 ■ 0 0 0 0
24 hr 0.02 0 0 0.01 ± 0.01
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plasma concentration was absent and the second more sustained peak was 
similar to that seen after oral administration.
Intra-abomasal administration resulted in a single plasma 
maximum occurring 2 hours after dosing. Maximum concentrations 
achieved by this route were lower and less sustained than by either of 
the other two routes.
The presence of meclofenamate in the abomasum within 10 
minutes of oral administration was almost certainly due to functioning 
of the reticular groove reflex, since no drug was detectable in the 
abomasum after intra-ruminal administration for over 1 hour after 
administration.
The concentrations of ræclofenamate in the rumen, abomasum, 
duodenum and plasma CFigs. 3 Cl) to 3 C3)) were all consistent with 
this view that a proportion of orally administered meclofenamate was 
delivered directly to the abomasum.
The abomasal and duodenal concentrations of meclofenamate 
at times later than 2 hours after intra-ruminal administration were 
considerably lov/er than after oral administration. Although only 
mean values are shown, this was found in each individual sheep.
These elevated concentrations after oral administration may have been 
due to slow passage and slow absorption of the proportion of the 
administered dose delivered to the abomasum, or, more probably, that 
some of the drug by-passing the rumen due to the reticular groove 
reflex was deposited in the omasum and that this amount was 
'responsible for maintaining abomasal and duodenal concentrations. 
McEwan and Oakley (1978) have shown in calves given anthelmintic
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drenches that, in these calves where the ruræn was by-passed, some or 
all of the drench was deposited in the omasum.
This latter view is also supported by the results of 
experiment 3 where abomasal and duodenal concentrations of meclofenamate 
were much lower than after oral aoministration although in this case 
the entire dose was deposited in the abomasum,
Meclofenamate was detectable at very low concentrations in 
the earlier rumen samples after intra-abomasal administration. The 
maximum concentration in all sheep occurred at 40 minutes after 
administration. This was the only time at which drug was detectable 
in one animal.
DISCUSSION
There is evidence in these experiments that closure of the 
reticular groove occurred in all tnree animals to a varying degree, 
as estimated by abomasal fluid concentration 10 minutes after dosing.
The very low plasma concentrations found in all three sheep 
for over an hour after intra-ruminal administration would suggest that 
absorption from the rumen, if it occurs, must be very slow relative to 
the rate of transfer across other parts of the gastro-intestinal tract.
At the pH of both plasma and rumen contents (in these sheep 5.6-7,0) 
meclofenamic acid (pk^ 3.76) is very extensively ionised but the 
theoretical equilibrium between plasma and rumen contents is about 10:1 
in favour of plasma.
It is interesting that meclofenamic acid was present in the rumen 
after intra-abomasal administraticn. The ratio of plasma:rumen fluio 
concentrations was generally much higher than the predicted ratio of 10:1,
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suggesting that diffusion across the ruminai epithelium was-extremely slew. 
Concentration and excretion of acidic drugs in the alkaline saliva of 
ruminants has been demonstrated by Rasmussen C19B3) and the large 
volumes of saliva produced by sheep (6-16 litres per day (Kay, I960)) 
might account partially or totally for the concentrations found in 
the rumen.
From the results of Experiments 1 and 3 it is apparent 
that intra-abomasal administration of meclofenamic acid did not mimic 
the delivery of drug to the abomasum via the reticular groove. Even 
allowing for the fact that the dose given intra-abomasally was only 
half of that given orally the maximum concentrations in plasma after 
intra-abomasal administration were lower and occurred much later than 
the initial plasma maximum seen after oral administration and the 
reason for this is not clear.
Drug entering the abomasum via the groove does so at the 
omasal/abomasal orifice which is considerably anterior to the site 
of the abomasal cannula, and it may be that the higher plasma 
concentrations are a reflection of the greater surface area which is 
thus available for absorption. Alternatively, administration of 
the drug via the cannula may result in smooth muscle contraction of 
the abomasal wall with rapid expulsion of drug forward into the more 
alkaline intestine which is a less favourable environment for 
absorption of an acidic drug,
A third explanation is that dissolution of the drug in the 
abomasum is so slow that this limits the absorption. The solubility 
of meclofenamic acid is less than 0,03 n^/ml in water and in abomasal 
fluid (pH 2-3) is much lower. Orally administered drug may undergo
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rrore rapid dissolution in the alkaline (pH 6.2) saliva and be 
immediately available for absorption.
In order to investigate this point it was decided to repeat 
Experiments 1 and 3 with the soluble sodium salt of meclofenamic acid,
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EXPERIMENTS WITH SODIUM MECLOFENAMATE
The saræ three sheep were used as for the earlier experiments. 
The dose rate was equivalent to 20 mg/kg of meclofenamic acid both 
orally (Experiment 4) and intra-abomasally (Experiment 5). In both 
cases the appropriate volume of sodium meclofenamate (Parke-Davis 
experimental) was made up to 20 ml with water.
Drug administration and sampling were carried out as in 
Experirmnts 1 and 3.
RESULTS
Plasma and gastro-intestinal fluid concentrations of 
meclofenamate after oral and intra-abomasal administration of sodium 
meclofenamate are shown in Tables 3 (13) to 3 (20).
Fig. 3 (5) represents the mean concentrations in
the different body compartments after oral administration.
The bi-phasic pattern of absorption seen after oral 
administration of meclofenamic acid was again evident. With the 
soluble form of the drug, however, the initial plasma maximum was 
much higher and occurred earlier, within 20 minutes of administration. 
The second maximum was much less marked end occurred later than after 
meclofenamic acid administration.
Intra-abomasally administered sodium meclofenamate gave 
rise to a single plasma maximum which occurred one hour after dosing. 
This was earlier than seen after meclofenamic acid but again later than 
the first plasma peak present after oral administration of the drug.
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TABLE 3 (13) PLASMA CONCENTRATION (yg/ml) OF MECLOFENAMATE AFTER
ORAL ADMINISTRATION OF SODIUM MECLOFENAMATE TO
3 SHEEP (20 mg/kg acid ecuivalent)
S h e e p  n u m b e r
Time 71 74 75 Mean ± S.E.M;
10 min 10.47 4.45 9.17 8,03 ± 1,83
20 min 11,69 5.94 8.00 8.54 ± 1,68
40 min 8.38 4.98 6.76 6,71 ± 0.93
1 hr 5.00 3.55 5.66 4.74 ± 0.62
In hr 5.00 3.34 4.55 4.30 ± 0.50
2 hr 5.00 2.97 3.97 3.98 ± 0.59
3 hr 2.77 2.37 5.66 3.60 ± 0.93
5 hr 4.46 3.07 3,58 3.70 ± 0.41
7 hr 6.00 3.55 4.62 4.72 ± 0,71
10 hr 5.92 2.30 2,54 3.59 ± 1,17
14 hr 2.62 1.66 1.74 2.01 ± 0.31
18 hr 2.46 1.15 0.76 1.46 ± 0,51
22 hr 2.15 0.49 ' 0.55 1.06 ± 0.54
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TABLE 3 (143 RUMINAL FLUID CONCENTRATION (yg/ml) OF MECLOFENAMATE
AFTER ORAL ADMINISTRATION OF SODIUM MECLOFENAMATE TO
3 SHEEP (20 mg/kg acid ecuivalent)
Titre
S h e e p n u m b e r
71 74 75 Mean ± S.E.M.
10 min 0.04 1.63 6.68 2.78 ± 2,00
20 min 2.44 4.60 5.49 4.18 ± 0,91
40 min 9.29 4.72 6.50 6.84 ± 1.33
1 hr 13,89 5.33 11.13 10.12 ± 2.52
In hr 9.16 6.54 9.01 8,24 ± 0.85
2 hr 9.41 5.57 6.15 7.71 ± 1.13
3 hr 5.89 4.32 5.56 5.26 ± 0.48
5 hr 4.71 2.65 4.15 3.64 ± 0.61
7 hr 2.71 0.65 2.66 2.01 ± 0.68
10 hr 0.78 0.52 0.61 0.64 ± 0.03
14 hr 0.39 0.14 0.09 0.21 ± 0,09
18 hr 0.25 0.10 0.03 0.13 ± 0.06
22 hr 0.25 0.06 0.07 0.13 ± 0,06
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TABLE 3 (15) ABOMASAL FLUID CONCENTRATION (yg/ml) OF MECLOFENAMATE
AFTER ORAL ADMINISTRATION OF SODIUM MECLOFENAMATE TO
3 SHEEP (20 mg/kg acid equivalent)
S h e e p  n u m b e r
Time 71 74 75 Mean ± S.E.M.
10 min 0 0.01 0.23 0.08 ± 0,03
20 min 0 0 0.37 0.12 ± 0.12
40 min 0.04 0.03 0.36 0.14 ± 0.11
1 hr 0.04 0.01 0.25 0.10 ± 0,03
U  hr 0.04 0.03 0.22 0.10 ± 0.06
2 hr 0.09 0.04 0.12 0.08 ± 0.02
3 hr 0.10 0.01 ■ 0.24 0.12 ± 0.07
5 hr 0.11 0.05 0.24 0.13 + 0.06
7 hr 0.08 0.01 0,06 0.05 ± 0.02
10 hr 0.02 0.03 0.03 0.03 ± 0.003 .
14 hr 0.16 0.01 0.05 0.07 ± 0.04
18 hr 0.05 0.01 0.03 0.03 ± 0.01
22 hr 0 0.02 0.03 0.02 ± 0.01
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TABLE 3 (16) DUODENAL FLUID CONCENTRATION (yg/ml) OF MECLOFENAMATE
AFTER ORAL ADMINISTRATION OF SGOIUM MECLOFENAMATE TO
3 SHEEP 2^0 mg/kg acid ecuivalent)
S h e e p  n u m b e r
Tirm 71 74 75 Mean ± S.E.M.
10 min 0 0 0.03 0.01 ± 0.01
20 min 0 0.03 0.31 0.11 ± 0.10
40 min 0.03 0.03 0.40 0.15 ± 0.12
1 hr 0.01 0.18 0.28 0.16 ± 0.08
U  hr 0.04 0.01 0.20 0.08 ± 0.06
2 hr 0.05 0.03 0.23 0.10 ± 0.06
3 hr 0.09 0.02 0.15 0.09 ± 0,04
5 hr 0.14 0.04 0.04 0.07 ± 0.03
7 hr 0.10 0 0.05 0.05 ± 0.03
10 hr 0.10 0.01 0.02 0.04 ± 0.03
14 hr 0,09 ■ 0.01 0 0.03 ± 0.03
IB hr 0.03 0,01 0.02 0,02 ± 0.01
22 hr 0.03 0 0 0.01 ± 0.01
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TABLE 3 (17) PLASflA CONCENTRATION (yg/ml) OF MECLOFENAMATE AFTER
INTRA-ABOiTASAL ADMINISTRATION OF SODIUM MECLOFENAMATE 
TO 3 SHEEP (20 mg/kg acid equivalent)
Time
S h e e p n u m b e r
71 74 75 Mean ± S.E.M.
10 min 1.57 3.58 0.81 2,65 ± 1.48
20 min 5.80 4,69 0.54 3.68 ± 1.60
40 min 10.47 3.26 0.44 4.72 ± 2.99
1 hr 14.86 3,25 0.54 6.22 ± 4.39
11 hr 9.74 4.33 0.25 4.77 ± 2.75
2 hr 4.73 5.14 1.26 3.71 ± 1.23
3 hr 2.16 3.50 2.31 2.66 ± 0.42
5 hr 2.36 2.67 1.98 2.34 + 0.20
7 hr 1.57 1.38 1.16 1.37 ± 0.12
ID hr 1.39 1.09 0.47 0.98 ± 0.27
24 hr 0.39 0.27 0.13 0.26 ± 0.08
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TABLE 3 (18) RUMINAL FLUID CONCENTRATION (yg/ml) OF MECLOFENAMATE 
AFTER INTRA-ABOMASAL ADMINISTRATION OF SODIUM 
MECLOFENAMATE TO 3 SHEER (20 mg/kg acid equivalent)
Titre
S h e e p n Ü tn b e 'r
71 74 75 Mean ± S.E.M.
10 tnin 0.08 0 0 0.03 ± 0.03
20 tnin 0.06 0.51 0.01 0.19 ± 0.16
40 min 0.19 0.08 0 0,09 ± 0.06
1 hr 0.11 0 0.18 0.10 ± 0.05
Is hr 0.02 0.04 0.03 0.03 ± 0.01
2 hr 0 0.01 0 0
3 hr 0.01 0 0 0
5 hr 0.03 0.05 0 0.03 ± 0.01
7 hr 0 0.04 0 0.01 ± 0.01
10 hr 0 ■ 0,02 0 0.01 ± 0.01
24 hr 0 0.01 0 0
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TABLE 3 (19) AEOMASAL FLUID CONCENTRATION (yg/ml) OF MECLOFENAMATE 
AFTER INTRA-ABOMASAL ADMINISTRATION OF SODIUM 
MECLOFENAMATE TO 3 SHEEP (20 ng/kg acid equivalent)
Time
S h e e p n u m b e r
71 74 75 Mean ± S.E.M,
10 min 7.85 33.29 2.05 14.40 ± 9.59
20 min 4.32 82.13 1.02 . 29.16 ±26.50
40 min 1.64 18.80 1.20 7.21 ± 5.79
1 hr 0.57 4.11 0.41 1.70 ± 1.21
Is hr 0.37 3.67 0.44 1.49 ± 1.09
2 hr 0.17 0.78 0.30 0.42 ± 0.19
3 hr 0.04 0.82 0.31 0.39 ± 0.23
5 hr 0.09 0.28 0.30 0.22 ± 0.07
7 hr 0.04 0.08 0.07 0.06 ± 0.01
10 hr 0.02 0.03 0.03 0.03 + 0.003
24 hr 0 0.06 0 0.02 ± 0.02
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table 3 (20) DUODENAL FLUID C0NCEÎ.TRATI0N (yg/ml) OF MECLOFENAMATE 
AFTER INTRA-ABOMASAL ADMINISTRATION OF SODIUM 
MECLOFENAMATE TO 3 SHEEP [20 mg/kg acid equivalent)
Time
S h e e D n u m b e r
71 74 75 Mean ± S.E.M.
10 min 2.42 18.41 1.51 7.45 ± 5.49
20 min 1.73 No S 2.14 1.94 ± 0.20
40 min 1.17 No S 1.56 1.38 ± 0.20
1 hr 0.60 4.62 1.21 2.14 ± 1.25
Is hr 0.26 3.79 0.73 1.60 ± 1.10
2 hr 0.31 2.55 0.45 1.10 ± 0.72
3 hr 0.50 1.55 0.40 0.82 ± 0.37
5 hr 0.05 0.72 0.35 0.37 ± 0.19
7 hr 0.04 0.07 0.23 0.11 ± 0.06
10 hr 0 ■ 0.06 0.02 0.03 ± 0.02
24 hr 0.18 0.23 0.05 0.15 ± 0.05
as
Fig, 3 C5) Mean plasma and gastro-intestinal fluid concentrations 
(yg/ml) of meclofenamate in three sheep after oral 
administration of sodium meclofenamate (20 mg/kg)
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The maximum concentration achieved was also lower than that after 
oral administration.
DISCUSSION
The soluble sodium salt of meclofenamate administered either 
orally or intra-abomasally gives rise to more rapid absorption than 
the relatively insoluble acid form of the drug. Plasma concentrations 
with the sodium salt are well maintained. All three sheep had higher 
plasma concentrations at 10 hours and later times when dosed with the 
sodium salt than with the acid, suggesting that the low aqueous 
solubility of msclofenamic acid at the normal pH of the gut limits 
its absorption.
The difference between delivery of drug to the abomasum via 
the reticular groove and experimentally administering it via the 
aborresal cannula is again obvious. The lower total absorption and 
delayed occurrence of the maximum concentration compared with oral 
administration are similar to that seen in Experiments 1 and 3.
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ABSORPTION OF MECLOFENAMIC ACID FROM THE ISOLATED RUMEN IN VIVO
In order to determine the rate and extent of absorption 
of meclofenamic acid through the rumen epithelium, an experiment was 
undertaken in which the reticulo-rumsn was isolated from the 
abomasum by ligation of the omasal/abomasal junction. The drug was 
administered via the rumen fistula and plasma concentrations of 
meclofenamate determined,
MATERIALS AND METHODS
The animal used was one in which the rumen cannula was 
of an unsatisfactory type and had been rejected. The animal was 
therefore to be killed.
Anaesthesia was induced with halothane via a mask and 
maintained with a halothane/oxygen mixture via an endotrachael tube 
throughout the duration of the experiment.
The omasal/abomasal orifice was located via a right 
paracostal incision and clamped with bowel clamps. Double trans­
fixion ligatures of thick surgical silk were used to tie off the 
junction. The clamps were removed and the abdominal incision 
closed.
A blood sample was taken before drug administration.
20 mg/kg of meclofenamic acid was given via the fistula. The rumen 
fistula was closed with bowel clamps throughout the duration of the 
experiment. A large bore needle was retained in the fistula to 
release the gas formed by ruminai fermentation. Blood samples were
taken 10 minutes, 20 minutes and 40 minutes, and 1, I5, 2, 3, 4, 5, 
and 6 hours after drug administration.
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At 1 hour and 6 hours abornasal fluid samples were also taken 
in order to verify that there was no leakage of drug past the ligature.
After the 6 hour sample was taken, meclofenamic acid was 
administered at a dose rate of 10 mg/kg as a slurry in 50 ml of water 
via the abornasal cannula.
Further blood sampling was then carried out at 10, 20, 30, 40 
and 60 minutes after intra-abomasal administration in order to ascertain 
whether or not the anaesthesia would significantly affect the absorption 
of the drug.
The animal was then killed by intravenous administration of 
sodium pentobarbitone CEuthatal, May and Baker] and the success of 
the surgical procedure verified at post-mortem. Plasma and abornasal 
fluid sarrples were assayed as described in Chapter 2 for meclofenamate.
RESULTS
The meclofenamate concentration in plasma was below the 
detectable limit in all samples up to 6 hours after intra-ruminal 
administration of the drug, as was that in both abornasal fluid samples.
Plasma concentrations of meclofenamate after intra-abomasal 
administration are shown in Table 3 [21],
DISCUSSION
Although no meclofenamate was detected in plasma sarrples 
after intra-ruminal administration, absorption of small amounts could 
have occurred at a slew rate such that because of redistribution, 
metabolism and excretion, the concentrations in plasma were always 
below the limit of detection of the analytical technique. Nevertheless
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TABLE 3 (21) PLASMA CONCENTRATIONS (pz/ml) OF MECLOFENAMATE AFTER 
INTRA-ABOMASAL ADMINISTRATION OF MECLOFENAMIC ACID TO 
A SHEEP WITH A LIGATED CMAEAL/AEOMASAL ORIFICE 
(DGSE RATE 20 ng/kg)
Time 
(mins, )
Plasma
Concentration
(pg/ml)
10 0.07
20 0.21
30 1.01
40 0.46
60 0.46
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this experiment does demonstrate that absorption from the rumen, if 
it occurs at all, is negligible compared with absorption from the 
abomasum.
The maximum concentration of meclofenamate achieved after 
intra-abomasal administration of meclofenamic acid to this sheep was 
of the same order as those achieved in normal non-anaesthetised 
animals.
The effects of the anaesthetic and surgical procedure on 
absorption are difficult to determine, reduced/abolished motility of 
the gut would be the major effect, and reduced blood flow to the rumen 
is a frequent result of the tying off procedure CAnnison, 1965).
CHAPTER 4 
STUDIES WITH LEVAMISOLE
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Levamisole CL-2,3,5,6”tetrahydro-6-phenylimldazo {2,1-6} 
thiazole) is widely used in several animal species as an anthelmintic. 
It has been shown to have good activity against adult and imrrature 
gastro-intestinal roundworms and against lungworms (Forsyth, 1956,
1968; Lyons, Drudge and Tolliver, 1968; Reid, Armour, Jennings and 
Urquhart, 1968; Ciordia and Baird, 1969).
Levamisole is not effective against cestodes or trematodes 
(Walley, 1966),. Reid, Duncan and Bairden (1976) have reported it 
to be effective against inhibited ostertagia spp in sheep but 
levamisole is ineffective against inhibited ostertagia ostertagi in 
cattle (Reid et al, 1968; Anderson, 1977). Levamisole is not 
ovicidal (Walley, 1966),
In the United Kingdom, levamisole is marketed as a drench, 
as a subcutaneous injection and as io-feed granules ("Nilveim", 
"Nemicide”, I.C.I). It is available for use in cattle, sheep, 
goats, pigs and poultry.
Fig. 4 (1) shows the structure of levamisole.
Although levamisole has been shown to inhibit the fumarate 
reductase system of nematodes (van den Eossche and Janssen, 1969; 
Prichard, 1973), it is generally thought to act primarily on the 
nervous system of the helminth. Wang and Saz (1974) found it to be 
effective against certain filarial v/orms which lack fumarate reductase. 
Aceves, Erlij and Martinez Maranon (1970), van Neuten (1972) showed 
a rapid contraction followed by paralysis of the worms which van K'euten 
(1972) suggested was due to stimulation of the ganglia of the
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Fig, 4 Cl) The structure of levamisole
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parasites. This author found that levamisole-induced contractions 
were inhibited by the ganglion-blocking agent hexaméthonium and 
similar inhibition has been found with other ganglion-blocking 
drugs, namely mecamylamine and pempidine (Coles, East and Jenkins, 
1975).
The paralysis caused by the drug allows expulsion of the 
parasite by the host gut or lung.
Eyre (1970) has shown tetramisole to have some anticholin­
esterase activity and this has been stated as a possible mode of 
action of levamisole (Meyer Jones, Booth and McDonald, 1977). 
Recent work, however, has shown that the cholinesterase-inhibitory 
action of levamisole is negligible (Henderson, 1960).
Levamisole was of interest in this study as a basic drug 
which is freely soluble at any pH encountered within the ruminant 
digestive tract as well as at the pH of blood plasma. It is the 
major anthelmintic used in ruminants in the United Kingdom, along 
with the benzimidazole drugs^and provides an interesting contrast 
to the latter group of compounds, both in its kinetics and its mode 
of action.
S4
EXPERIMENTS WITH LEVAMISOLE
Plasma, abornasal fluid and ruminai fluid concentrations of 
levamisole were measured in four sheep after oral, intra-ruminal and 
subcutaneous administration of levamisole hydrochloride,
MATERIALS AND METHODS
In all experiments the dose was 7,5 mg/kg of the hydro­
chloride salt. Commercial "Nilverm" v.orm drench was used for oral 
and intra-ruminal administration and commercial "Nilverm" injection 
for subcutaneous administration. The oral dose was given using a 
syringe placed at the back of the tongue of the animal, intra- 
ruminal administration was via the cannula and subcutaneous injection was 
given over the ribs, behind the point of the elbow.
The three administrations were made at 14 day intervals, 
the same four sheep were used throughout and the routes used in any 
sheep on any experin^ntal day were randomised.
Blood and gastro-intestinal fluid samples were taken as 
described in Chapter 2 before drug administration and at 10 minutes,
30 minutes, 1, 2, 4, 6, 8 and 24 hours after administration. Samples 
were later analysed for levamisole free base concentration as 
described in Chapter 2,
RESULTS
The plasma, abornasal fluid and ruminai fluid concentrations 
of levamisole after subcutaneous,oral end intra-ruminal administration 
are shown in Tables 4 Cl), 4 (2) and 4 C3).
Mean plasma and abornasal fluid concentrations by all routes
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TABLE 4 (1) PLASMA CONCENTRATIONS OF LEVAMISOLE Cyg/ml FREE EASE]
AFTER SUBCUTANEOUS, ORAL AND INTRA-RUMINAL ADMINISTRATION
TO 4 SHEEP (7.5 mg/kg HYDROCHLORIDE)
Tirm Spot
S h e e p
Ger
n a m e
Brian Ben Mean ± S.E.M.
SUBCUTANEOUS ADMINISTRATION
10 min 1.35 1.25 0.71 1.13 1.11 ± 0.14
30 min 3.42 3.14 1.76 3,26 2,90 ± 0.33
1 hr 3.75 2.97 1.89 3,69 3.08 ± 0,43
2 hr 2.85 2.49 0.77 2,88 2,25 ± 0.50
4 hr 1.75 1.57 0.21 1.69 1.31 ± 0.37
6 hr 0,89 1.04 0.12 1.22 0.82 ± 0,24
8 hr 0.54 0.81 0.09 0.88 0,61 ± 0.18
24 hr 0.10 0.11 0,08 0.11 0.10 ± 0.01
ORAL ADMINISTRATION
10 min 0.36 0.77 0.40 0.59 0.53 ± 0.09
30 min 0.68 0.48 0.38 0.46 0.50 ± 0.06
1 hr 0.78 0,59 0,36 0.46 0.55 + 0.09
2 hr 0,93 0,84 0,42 0.51 0,68 ± 0,12
4 hr 1.04 0.97 0,13 0.62 0,69 ± 0,21
6 hr 0,95 0.95 0.04 0.90 0,71 ± 0.22
8 hr 0.82 0.85 0.05 0,75 0.62 ± 0.19
24 hr 0.16 0.17 0.00 0.00 0.08 ± 0,05
INTRA-RUMINAL ADMINISTRATION
10 min 0.00 0.10 0.30 0.38 0,20 ± 0.09
30 min 0.23 0.30 0.64 0.65 0,46 ± 0,11
1 hr 0.59 0.48 0,52 0,72 0.58 ± 0,05
2 hr 0.88 0.71 0.35 0.67 0.65 ± 0.11
4 hr 1.10 0,98 0.28 0.65 0,80 ± 0.18
6 hr 0.91 1.15 0.17 0.89 0.78 ± 0.21
8 hr 0.84 0.99 0.15 0.74 0.68 ± 0.16
24 hr 0.15 0.42 0,06 0,15 0.20 ± 0.08
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TABLE 4 C2) ABGMASAL FLUID CüNCB\TRATIONS OF LEVAMISOLE Cyg/ml FREE 
BASE) AFTER SUBCUTANEOUS, ORAL AND INTRA-RUMINAL
ADMINISTRA'TION TO 4 SHEEP C7.5 r.yg/kg HYDROCHLORIDE)
Time
S i
Spot
h e e □ 
Ger
n a m e
Brian Ben Mean ± S.E.M.
SUBCUTANEOUS ADMINISTRATION
10 min 1.72 1.51 1.23 0.85 1.33 ± 0.19
30 min 10.67 11.03 8.02 6.17 8.97 ± 1.15
1 hr 15.43 19.89 ■' 18.56 12.33 16.55 ± 1.69
2 hr 24.54 18.68 13.68 22.00 19.83 ± 2.29
4 hr 48,60 33.25 12.25 39.12 33.31 ± 7.70
6 hr 26.24 40.06 4.29 30.83 25.36 ± 7.59
8 hr 14.56 27.09 1.73 17.34 15.19 ± 5.23
24 hr 0.82 2.89 0.00 2.06 1.44 ± 0.64
ORAL ADMINISTRATION
10 min 196.24 4.49 70.14 379.25 162,53 ± 82.47
30 min 201.72 13.50 100.72 340,52 164.12 ± 70.26
1 hr 119.18 65.75 67.44 265.66 129.51 ± 47.05
2 hr 106.34 18.22 43.16 202,15 92.47 ± 40.99
4 hr 45.44 24.22 9.89 94.75 43.58 ± 18.56
6 hr 22.70 27.32 7.82 35.90 23.44 ± 5,88
8 hr 14.63 30.76 4.92 17.83 17.04 ± 5.34
24 hr 1.60 4.24 0.18 1.25 1.82 ± 0,86
INTRA-RUMINAL ADMINISTRATION
10 min 0.00 0.00 0,00 0.00 0.00
30 min 0.22 3.46 0.79 0.00 1.12 ± 0.79
1 hr 2.34 11.13 3.72 5,07 5.57 ± 1.94
2 hr a. 10 15.06 4.85 7.43 9.11 ± 2.16
4 hr 19.78 23.63 6.06 14.07 15.94 ± 3.85
6 hr 31.51 27.72 6.49 17.09 20.73 ± 5.65
6 hr 25.25 27,09 5.47 14.47 18.32 ± 5.15
24 hr 4.79 9.34 0.72 2.49 4.34 ± 1.86
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TABLE 4 (3) RUMINAL FLUID CONCENTRATIONS OF LEVAMISOLE (yg/ml
FREE EASE) AFTER SUBCUTANEOUS, ORAL AND INTRA-RUMINAL
ADMINISTRATION TO 4 SHEEP (7.5 mg/kg HYDROCHLORIDE)
Time Spot
S h e e p
Ger
n a m e
Brian Ben Mean ± S.E.M.
SUBCUTANEOUS ADMINISTRATION
10 tnin 0.00 0.00 0.00 0.00 0
30 min 0.00 0.00 0,00 0.00 0 •
1 hr 0.05 0.38 0.00 0.10 0.13 + 0.08
2 hr 0.19 0.56 0.00 0.57 0.33 ± 0.14
4 hr 0.37 0.91 0.01 0.40 0.42 ± 0.19
6 hr 0.40 0,91 0.01 0.40 0.43 ± 0.18
8 hr 0.16 0.88 0.00 0.20 0.31 ± 0.19
24 hr 0.11 0.29 0.00 0.11 0.13 ± 0.06
ORAL ADMINISTRATION
10 min 14.09 22.15 0.15 0.63 9.26 ± 5.38
30 min 16.68 11.81 2.83 9.96 10.32 ± 2.87
1 hr 8.31 9.91 3.73 6.51 7.12 ± 2.65
2 hr 1.16 7.17 4.50 12.49 6.33 ± 2.39
4 hr 0.87 4.05 2.58 2.33 2.46 ± 0.65
6 hr 0.58 2.67 1.67 0.71 1.46 ± 0.53
8 ’hr 0.00 1.77 0.91 0.47 0.79 ± 0.38
24 hr 0.00 0.36 0.06 0.13 0.14 ± 0.08
INTRA-RUMINAL ADMINISTRATION
10 min 33.25 82.03 0.06 1074.11 297.36 ± 259.46
30 min 48.41 14.68 0.64 134.70 49.71 ± 30.04
1 hr 33.34 9.30 0.26 97.26 35.04 ± 21.88
2 hr 15.38 7.76 2.04 153.21 44.60 ± 36.31
4 hr 7.94 5.71 4.65 16.74 6.76 ± 2.75
6 hr 3.59 3.92 3.97 2.95 3.61 ± 0.23
8 hr 2.43 2.60 1.40 1.27 1.98 ± 0.38
24 hr 0.22 0,78 0.07 0.19 0.32 ± 0.16
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are shown in Figs. 4 (2) and 4 (3) respectively.
Plasma concentrations were higher and the maximum 
concentrations achieved occurred much earlier after subcutaneous 
administration than by either of the other two routes. After oral 
administration and intra-ruminal administration plasma concentrations 
were similar except at ten minutes after dosing when all four sheep 
had higher concentrations after oral administration. This was 
probably due to the influence of the reticular groove reflex* high 
concentrations of levamisole were found in the abomasum of all the 
sheep by 10 minutes after the oral dose. No levamisole was detected 
in the abomasum after intra-ruminal administration until the 30 minutes 
sample in three sheep and until one hour in the fourth animal.
Abornasal fluid concentrations were highest when the drug was 
administered orally. Higher concentrations in abornasal fluid were 
found after subcutaneous administration than after intra-ruminal.
Ruminai fluid concentrations were significantly higher in 
all sheep after intra-ruminal administration than after oral dosing, 
supporting the suggestion that sorre of the orally administered drug 
by-passed the rumen,
Levamisole was detected in the ruminai fluid of all sheep 
after subcutaneous administration. The concentrations found varied 
widely in different animals.
The bio-availability of levamisole after subcutaneous 
administration v/as much greater than that after oral or intra-ruminal 
administration. The area under plasma concentration time curve was 
in the ratio 2.4:1.07:1.0 for subcutaneous, intra-ruminal and oral
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Fig, 4 (2) Mean plasma concentrations (yg/ml) of levamisole in four
sheep after subcutaneous, intra-ruminal and oral administration
of levamisole (7.5 mg/kg)
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Fig. 4 C3) Mean abornasal fluid concentrations (yg/ml) of levamisole 
in four sheep after subcutaneous, intra-ruminal and oral 
administration of levamisole (7.5 mg/kg)
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routes respectively.
DISCUSSION
Plasma concentrations of levamisole found in these sheep 
after oral administration were lower than those found by Allev/ijn 
and Derroen (1965) cited by Graziani and De Martin (1977) in a 
calf. These authors reported plasma concentrations of up to 
6 ]jg/ml in a calf dosed orally with 10 mg/kg of tetramiscle. The 
age of the calf was not given and since the peak plasma concentration 
occurred at 30 minutes, it seems probable that it was a pre-ruminant 
animal.
Dom and Federmann (1976) in their comparative study of 
plasma concentrations after oral subcutaneous and pour on 
administration of levamisole to calves, found similar blood levels 
after oral administration to those reported here. Plasma 
concentrations after subcutaneous administration in these sheep, 
however, were much higher than those found by Dom and Federmann 
(1976) after a similar dose.
Because of the mode of action of levamisole, it might be 
expected that it is the peak concentration of the dr\jg at the site 
of action that is important in the determination of anthelmintic 
activity. If this is so, then these studies suggest that the 
subcutaneous route which achieves higher plasma concentrations (and 
therefore higher lung concentrations) would be the route of choice 
for treatment of Dictyocaulus infection, and the oral route which 
achieves higher abomasal concentrations would be the better route 
for treatment of gastro-intestinal helminthiasis.
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The low abomasal fluid concentrations seen after intra- 
ruminal administration of levamisole suggest that the functioning of 
the reticular groove after oral administration, which was apparent in 
all four sheep, may be important in determining anthelmintic efficacy. 
Ruminai fluid concentrations of levamisole in many of the 
samples after intra-ruminal administration of the drug were lower 
than would be expected from simple dilution of the drug by rumen 
contents. Dobson C1967) cites a 50 kg sheep as having a 5-10 kg of 
reticulo-ruminal contents. If a dose of 7,5 mg/kg.of levamisole was 
evenly distributed throughout the ruminai contents, the expected 
concentrations would be about 37,5-75 yg/ml, in fact the concentrations 
found in these sheep were considerably lower, with the exception of 
some of the very early samples where mixing was obviously incomplete. 
This was particularly striking in the case of one animal (Brian) in 
which the maximum ruminai fluid concentration of levamisole measured 
was less than 5 yg/ml.
One possible explanation for these findings is that some 
adsorption of the drug to the fibrous material of the rumen occurred.
Since the assay procedure involved centrifugation of runnen 
sarrples followed by filtration of the supernatant fluid, any drug 
adherent to the solid material would not have been measured.
Alternatively levamisole may have been degraded to some 
extent by ruminai micro-organisms. The drug was not incubated with 
ruminai fluid in vitro, so this possibility cannot be discounted. No 
metabolites were evident on HPLC analysis of ruminai fluid extracts 
for the parent drug.
Either of these mechanisms, adsorption or degradation, may
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have been responsible for the much lower bio-availability of 
levamisole when given orally and intra-ruminally than when 
administered by subcutaneous injection.
The third explanation for the low ruminai fluid 
concentrations found after intra-ruminal administration is that 
absorption of levamisole occurs through the ruminai epithelium. The 
evidence in favour of this explanation is that levamisole was 
detected in the plasma of three of the four sheep by 10 minutes after 
administration, but not in the abomasal fluid at this time.
Passive diffusion of levamisole into the gut after 
subcutaneous administration was observed. This accumulation of basic 
drug in the acidic regions of the gut by the process of 'ion trapping' 
was not unexpected. The theoretical equilibrium ratio of levamisole 
which has a pkg of 8 between plasma CpH 7,43 and ruminai fluid (pH 6.6) 
and plasma and abomasal fluid CpH 2.5), would be approximately 1:5 
and 1:63,000 in favour of the rumen and abomasum respectively for 
free unbound drug. The ratios measured in this study were at 
greatest 1:2.64 and 1:58 respectively for any animal,
Parenterally administered levamisole may have reached the 
rumen via the saliva rather than across the ruminai wall. At pH 
of saliva (8,2) levamisole would be expected to attain concentrations 
which at equilibrium (which is never achieved because of constant 
salivary excretion) would approach one-third of those in plasma*
CHAPTER 5 
STUDIES WITH BEN'ZIMIDAZOLES
104
The benzimidazoles are, along with levamisole, the most 
important broad spectrum anthelmintics currently marketed. Nine 
members of the group are available in the United Kingdom; all 
have a similar basic structure with differing side chain constituents 
at positions 2 and 5.
Fig. 5 Cl) shows the structure of the different 
benzimidazoles and the species for which they are marketed in the 
United Kingdom.
Thiabendazole, the first of the group, was introduced in 
1961 and was followed by parbendazole, cambendazole, mebendazole and 
oxibendazole. These early benzimidazoles have good activity against 
mature gastro-intestinal nematodes in cattle, sheep and many other 
species (Baker and Douglas, 1962; Actor, Anderson, Dicuollo,
Ferlauto, Hoover, Pagano, Ravin, Scbeidy,■ Stedman and Theodorides, 
1967; Baker and Walters, 1971; Brugmans, Thienpont, Van Wijngaarden, 
Vanparijs, Schuermans and Lauwers, 1971; Theodorides, Chang,
Dicuollo, Grass, Parish and Scott, 1973), They are less effective 
against immature helminths and only mebendazole has activity against 
lungworms and tapeworms at normal dose levels.
The rrare recently marketed benzimidazoles - fenbendazole, 
oxfendazole and albendazole - are active at lov/er dosage rates and 
also have an extended spectrum of activity, Fenbendazole, 
introduced in 1974, was the first anthelmintic shown to be effective 
against inhibited larval stages of the important abomasal parasite 
of cattle Dstertagia ostertagi (Duncan, Armour, Eairden, Jennings
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Fig, 5 (1) The structures and trade-names of the benzimidazole 
anthelmintics and the species for which they are 
marketed in the United Kingdom
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and Urquhart, 1976). It is also extremely effective against lung­
worms in cattle (Duwel, 1974) and sheep (Ross, 1975) and has recently 
been shown to have some activity against liver flukes and tapeworms 
(Corta, Lietava, DÜwel and Reisenleiter, 1979),
Oxfendazole, marketed scon after fenbendazole, has a 
similarly broad spectrum of activity (Downey, 1976; Chalmers, 1977, 
1978; Corwin, 1977; Lyons, Drudge and Tolliver, 1977) and albendazole, 
the most recent of the three, in addition has good flukicidal activity 
at only a slightly increased dose rate (Theodorides, Gyurik, Kingsbury 
and Parish, 1976). Recently rarketed (1980) in the United Kingdom 
only for pigs is flubendazole, a very close analogue of mebendazole.
Several of the benzimidazoles have been shown to inhibit the 
fumarate reductase system of helminths (Prichard, 1970, 1973, 1978; 
Malkin and Camacho, 1972; Rcmanowski, Rhoads, Colglazier and Kates,
1975) which interferes with energy production by the parasite. Eorgers 
and De Collin (1975); De Brabander and Thienpont (1975) have demon­
strated the effects of mebendazole on the ultrastructure of helminths. 
These authors reported disruption of the microtubules in the cytoplasm 
of the parasite cells, particularly the absorptive cells of the gut.
The loss of microtubules, which occurs within a few hours of exposure, 
leads to an accumulation of secretory granules, eventual lysis of 
cells, and consequent loss of absorptive function of the parasite.
The same authors reported a marked decrease in glycogen 
content of the parasites after a few hours of exposure to the 
benzimidazole, and reduced uptake of low molecular weight nutrients, 
including glucose, has been demonstrated previously in nematodes
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treated with mebendazole (Van den Bossche and De Nollin, 1973).
It is not knoivn which mechanism (enzyme inhibition or 
microtubular disruption) is the cause of death in the parasites, but 
it is probable that failure of glucose uptake would in itself 
eventually cause loss of fumarate reductase activity. Either of 
these possible mechanisms of anthelmintic activity would require the 
duration of exposure of the parasite to the drug, as well as the drug 
concentration achieved, to be important in determining efficacy.
It has been suggested that the benzimidazoles all have a 
similar mode of action and that differences in potency and spectrum 
of activity between members of the group may be due to differences 
in the pharmacokinetics of the drugs (Prichard, Hennessy and Steel,
1976), This is supported by the fact that the later, more 
potent benzimidazole drugs have much slower absorption and elimination 
than the earlier members of the group.
Maximum plasma concentrations of thiabendazole are reached 
4 hours after oral administration to sheep (Tocco, Buhs, Brown,
Matzuk, Mertel, Harman and Trenner, 1964), and of oxibendazole and 
parbendazole by 6 hours (Theodorides et al, 1973; Dicuollo, Miller, 
Mendelson and Pagano, 1974), In contrast, maximum plasma 
concentrations of fenbendazole and oxfendazole occur at around 24 
hours (Düwel et al, 1975; Prichard et al, 1978) and of albendazole 
at 15 hours (Dicuollo, Miller, Colman,Kraeer and Wong, 1977) after 
oral administration to sheep. Prichard et al ■ (1978) have also 
shown that even thiabendazole is effective against inhibited 
ostertagia larvae in cattle if drug concentrations are maintained by
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continuous or frequently repeated administration. Previously 
thiabendazole has been shown to be ineffective against inhibited 
lar\/ae (Armour, 1969, 1975; Anderson, 1977).
It appeared, theirefore, that a study of the kinetics of the 
benzimidazoles might be of use in further understanding of the action 
of these drugs and also allow a moro rational appiroach to the divided 
dose regimes which are required for good activity in monogastric 
animals, and which give improved activity in ruminant animals, 
(Gaenssler, Wilkins and O'Donnovan, 1978; Thienpont, Vanparijs,
Niemegeers and Marsboom, 1378).
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EXPERIMENTS WITH FENBENDAZOLE
Fenbendazole C5 phenylthio-benzimidazole-B-methyl 
carbamate) is marketed in the United Kingdom for use in cattle, sheep, 
pigs and horses. It is formulated as a suspension, as a powder and 
as granules "Panacur”, Hoechst) for oral use only.
Fenbendazole has been measured by Duv/el et al, (1975) in 
the plasma of sheep, cattle and other species. Using their 
fluorescence method, these authors reported maximum plasma concen­
trations of between 0,2 and 0,4 yg/ml occurring 6-24 hours after 
administration at a dose rate of 5 mg/kg to sheep. In cattle at 
this dose rate plasma concentrations were slightly higher and reached 
a maximum at about 30 hours in nrast animals. No drug was detected 
by 96 hours after treatment, Prichard et al (1978) have reported 
plasma and abomasal concentrations of labelled fenbendazole in 
cattle after intra-ruminal administration. In their studies 
maximum drug concentrations of 0,6 and 6.0 yg/ml were found in 
plasma and abomasal fluid respectively by about 24 hours after 
administration of 5 mg/kg,
DUwel (1977) has also measured the terminal metabolites of 
fenbendazole in urine and faeces of sheep, but the plasma 
concentrations of metabolites were not reported. None of these 
studies, therefore, has provided reliable data on plasma concen­
trations of fenbendazole since, because of the methods used for 
estimation of the drug, they do not distinguish parent drug and 
metabolites.
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Fig, 5 C2) The structures of fenbendazole and its ma lor metabolites
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In this study plasma, abomasal fluid and ruminai fluid 
concentrations of fenbendazole and its two major metabolites CFig.
5 (2)] were measured in six sheep after oral administration (Experiment 
1). In three of these sheep plasma concentrations were also measured 
after intra-abomasa1 administration (Experiment 2) and after intra- 
ruminal administration (Experiment 3),
MATERIALS AND METHODS
Fenbendazole ("Fanacur", Hoechst) was administered in all 
cases as a 2,5% suspension at a dose rate of 10 mg/kg. The oral 
dose was given using a syringe placed on the back of the animal's 
tongue and intra-ruminal and intra-abomasal doses were administered 
via the respective cannulae.
The oral administration was made to three sheep on two 
occasions. The first experiment was designed on the basis of the 
data published by Düwel et al (1975), Three sheep v/ere used and 
sampling was carried out before drug administration and at 4, 8,
12, 16, 20, 24, 30, 36, 48, 72, 96 and 120 hours (5 days) after 
administration. An additional abomasal fluid sample was taken at 
10 minutes. When the samples were assayed and fenbendazole found 
to be present in the 120 hour sample, it was decided to reseat the 
experiment with less frequent sampling but over a longer period of 
time. This was done several months later using different sheep.
The original three sheep were used for the intra-abomasal 
experiment, and for the intra-ruminal administration. Unfortunately 
one of these animals lost its ruminai cannula during the course of 
this experiment and had to be destroyed.
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The taking of sanples, the procedure for storage and 
method of assay for fenbendazole and its metabolites were all as 
described earlier in Chapter 2.
RESULTS
When samples of plasma and abomasal fluid were subjected 
to HPLC analysis for fenbendazole estimation, an additional, 
chromatographic peak with a retention time shorter than that of 
fenbendazole was observed in both plasma and abomasal fluid extracts. 
At that time the identity of the metabolites of fenbendazole was not 
known, and the concentration could not be measured directly.
Hov/ever, it was clear that this metabolite was quantitatively 
important since in many of the samples the peak height of the 
metabolite was greater than that of fenbendazole. Later, when by 
analogy with the concurrent albendazole study, it was suspected that 
the probable metabolic route for fenbendazole vjas via the sulfoxide 
of fenbendazole (which is itself marketed as oxfendazole), and the 
sulfone, sarrples of these compounds were obtained by gift from the 
manufacturers of oxfendazole (Syntex). When these authentic samples 
of sulfoxide and sulfone were subjected to HPLC they both had 
retention times equal to that of the metabolite peak seen in the 
fenbendazole samples. Using other HPLC solvents, as outlined in 
the Methods section, the sulfoxide and sulfone could be separated.
Further identification of the sulfoxide was obtained by 
collecting the appropriate fraction of the HPLC eluent from a number 
of injections, evaporating these and subjecting the residue to infra­
red spectroscopy. This residue was found to have an absorption
113
band at 1037 cm typical of a sulfoxide grouping, Conrparison 
of the infra-red spectrum of this compound with that of authentic 
fenbendazole sulfoxide confirmed the identity of this HPLC peak.
The "sulfone" peak identity was not unequivocally identified but had 
similar HPLC characteristics to that of authentic sulfone. Further 
samples of plasma were, therefore, analysed for the quantitation of 
the sulfoxide and sulfone separately.
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Table 5 (1) Plasma and aborrasal fluid concentrations of fenbendazole,
oxfendazole and oxfendazole sulfone after oral administration 
of fenbendazole (10 mg/kg) as a suspension
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TABLE 5 (23 RUMINAL FLUID CONCENTRATIONS (yg/rr.l3 OF FENBENDAZOLE
AFTER ORAL ADMINISTRATION OF FENBENDAZOLE (10 mg/kg)
AS A SUSPENSION
Tirre
S h e e p n a m e
Mean ± ELE.n.M S B E R G
Baseline 0 0 0 0 0 0 0
30 min - — - - -  " - '
4 hours 6.12 0.80 4.50 - - - 3.61 ± 1.57
8 4.27 0.96 6.67 0,97 1.84 0.43 2.52 ± 1.00
12 5.52 0.57 2.79 0.30 0.28 0.19 1.61 ± 0.68
16 3.75 0.27 1.55 0.27 0.19 0.19 1.04 ± 0.58
20 2.79 0.40 2.97 - - 2.05 ± 0.83
24 3.07 0.33 6.10 0.21 0.19 0.26 1.69 ±, 0.99
30 2.56 0.30 2.97 - - 1.94 ± 0.83
36 2.05 0.37 3.75 0.12 0.17 0.13 1.10 ± 0.61
48 1.93 0.20 2.17 0.08 0.14 0.05 0.76 ± 0.41
72 1.51 0.00 1.71 0.02 0.05 0.03 0.55 ± 0.34
96 0,84 0.10 2.64 0.01 0.02 0.01 0.60 ± 0.43
5 days 0.54 0.07 1.71 0 0 0 0.39 ± 0.28
7 - - - 0 0 0 0
6 - - - 0 0 0 0
9 - - - 0 0 0 0
11 - - — 0 0 0 0
14 - - — 0 0 0 0
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Fig. 5 (3) Mean plasma concentrations (yg/ml3 of fenbendazole, 
oxfendazole and oxfendazole sulfone in six sheep 
after oral administration of fenbendazole (10 mg/kg) 
as a suspension
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Fig. 5 C4) Mean abomasal fluid concentrations [yg/ml) of
fenbendazole, oxfendazole and oxfendazole sulfone 
in six sheep after oral administration of fenbendazole 
CIO mg/kg) as a suspension
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EXPERIMENT 1
Plasma, abomasal fluid and ruminai fluid concentrations 
of fenbendazole, and plasma and abomasal fluid concentrations of 
its major metabolites, oxfendazole and the sulfone, are shown in 
Tables 5 Cl) and 5 C2). Figs. 5 C3) and 5 C4) show the mean 
concentrations of fenbendazole and its metabolites in plasma and 
abomasal fluid respectively.
Maximum plasma concentrations of fenbendazole were 
variable and low, less than 0.3 yg/ml in any sheep; but persisted 
for up to 5 days. The maximum concentration occurred at around 
24 hours in most animals. The major metabolite, oxfendazole, was 
detectable in plasma by 4 hours after drug administration and 
reached its maximum concentrations at 30 hours. In all six sheep 
the maximum oxfendazole concentration was much higher than that of 
the parent drug.
The sulfone was detectable by 8-12 hours after adminis­
tration of fenbendazole and maximum concentrations were found at 
36 hours. The sulfone was present in lower amounts than the 
sulfoxide.
Fenbendazole was present in the abomasum by 10 minutes 
after administration in all animals, and was detectable for up to 
5 days. In two of the three sheep dosed in the initial experiment, 
abomasal fluid concentrations were fairly high at 5 days, and it is 
almost certain that if the sampling period had been extended, 
fenbendazole would have been detectable for greater than 5 days in 
these animals. The metabolites were detected in abomasal fluid
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at 4 hours (oxfendazole) and 20 hours (sulfone) and reached 
maximum concentrations by 48 and 72 hours respectively. Concen­
trations of both metabolites in the abomasum were lower than those 
of the parent drug, Oxfendazole reached higher concentrations in 
abomasal fluid than in plasma, but the sulfone did not.
Ruminai fluid concentrations of fenbendazole were extremely 
variable. The drug persisted for 4 days in three animals and for 
at least 5 days in the other three.
In some sheep it could definitely be stated that no 
oxfendazole or sulfone was detectable in the ruminai fluid at any 
time at the limit of detection for ruminai fluid (0,05 yg/ml). In 
others, because of difficulties already referred to (poor limit of 
detection for sulfoxide using methanol/perchloric acid; contamin­
ation of ruminai fluid sarrples) and also in some cases due to 
insufficient sample remaining after the initial measurement of 
fenbendazole, it is possible that low concentrations of these 
metabolites were present,
EXPERIMENT 2
The concentrations in plasma of fenbendazole and of total 
metabolites after intra-abomasal administration of fenbendazole are 
shown in Tables 5 (3) and 5 (4), Fig. 5 (5) shows mean plasrra 
fenbendazole concentrations after intra-abomasal administration 
compared with those after oral administration. In only one animal 
(M) were the metabolites measured separately. The relative 
percentages of sulfoxide and sulfone present at any time were 
similar to those found after oral administration.
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TABLE 5 (3) PLASMA CONCENTRATIONS Cug/rrl] GF FENBENDAZOLE
AFTER INTRA-AEOMASAL ADMINISTRATION OF FENBENDAZOLE
(10 mg/kg) AS A SUSPENSION
T irne
S h e e
M
p n a m e  
S B Mean ± S.E.M.
Baseline 0 0 0 0
30 min 0.03 0.01 0 0,013 ± 0,009
2 hours 0.13 0.05 0.08 0.09 ± 0.02
4 0.10 0.09 0.08 0.09 ± 0.01
6 0.10 0.08 0.11 0.10 ± 0,01
8 0.10 0.07 0.10 0.09 ± 0.01
12 0.16 0.06 0.15 0.12 ± 0.03
16 0.14 0.02 0.08 0.08 ± 0.03
20 0.14 0.02 0.07 0.08 ± 0.03
24 0.07 0.03 0.06 0.06 ± 0.01 .
30 0.06 0.02 0.06 0.05 ± 0.01
48 0.03 0.01 0,03 0,02 ± 0.01
72 0.02 0.01 0.01 0.013 ± 0.003
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TABLE 5 (4) PLASMA CONCENTRATION Cyg/ml) OF METABOLITES AFTER
INTRA-ABGMASAL ADMINISTRATION OF FENBENDAZOLE
CIO mg/kg) AS A SUSPENSION
S h e e p n a m e
TilTB M*
Sulfoxide Sulfone
S B Mean ± S.E.M.
Baseline 0 0 0 0 0
30 minutes 0 0 0 0 0
2 hours 0.02 0 0.02 0.03 0.02 ± 0.003
4 0.04 0 , 0.09 0.07 0.07 ± 0.01
6 0.07 0.01 0.15 0.18 0.14 ± 0.03
8 0.12 0.01 0.17 0.21 0.17 ± 0.02
12 0.22 0.03 0.20 0.33 0.26 ± 0.04
16 0.23 0.05 0.13 0.33 0.27 ± 0.07
20 0.31 0.06 0.09 0.34 0.27 ± 0.09
24 0.28 0.06 0.08 0.36 0.26 ± 0.09
30 0.19 0.07 0.07 0.33 0.22 ± 0.08
48 0.12 0.06 0,06 0.31 0.18 ± 0.07
72 0.08 0.06 0.02 0.15 0.10 ± 0.04
* Only in Sheep M were sulfoxide and sulfone measured separately
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Fig. 5 C5) Mean plasma concentrations (yg/ml) of fenbendazole after 
oral and intra-abomasal administration of fenbendazole 
(10 mg/kg) to the same three sheep
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In the initial 12 hour period after administration plasma 
concentrations of fenbendazole and its metabolites after intra- 
abomasal administration were higher than those after oral administration. 
At all times after this, drug and metabolite concentrations were lower, 
and they persisted for a shorter period than after oral administration. 
The area under the plasma concentration-time curve from Fig. 5 (5) 
after extrapolating to zero is in the ratio 3,2:1 for oral : abomasa1 
administration.
Ruminai fluid samples v/ere also taken and assayed in 
this experiment. No fenbendazole nor its metabolites were detected 
in any of these samples.
EXPERIMENT 3
Plasma concentrations of fenbendazole and of total 
metabolites after intra-ruminal administration are shown in Tables 
5 C5) and 5 C6). Oxfendazole and the sulfone were not measured 
separately. Since figures are available from only two animals for 
this experiment it is difficult to make valid comparisons. Plasma 
concentrations of fenbendazole and total metabolites after intra- 
ruminal administration were generally higher and more prolonged 
than after intra-abomasa1 administration. However, the maximum 
fenbendazole concentration was achieved earlier (IB hours) and 
the drug was less persistent than in the same t\--/o sheep after oral 
a chii n i s t ra t i on,
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TABLE 5 (5) PLASMA CONCENTRATIONS (Tg/ml) OF FENBENDAZOLE AFTER
INTRA-RUMINAL ADMINISTRATION Or FENBENDAZOLE (10 mg/kg)
AS A SUSPENSION
Time
S h e e p
M
n a m e
B Mean
Baseline 0 0 0
4 hours 0.10 0.09 0.01
8 0.10 0.15 0.13
IB 0.18 0.16 0.17
24 0.07 0.12 0.10
32 0.08 0.15 0.12
40 0.06 0.16 0.09
48 0.07 0.08 0.08
60 0.02 0.06 0.04
72 0 0.06 0.03
96 0 □ Ù
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TABLE 5 C6 3 PLASMA CONCENTRATIONS (pg/ml) OF METABOLITES AFTER
INTRA-RUMINAL ADMINISTRATION OF FENBENDAZOLE (10 mg/kg)
AS A SUSPENSION
Time
S h e e p
M
n a m e
B Mean
Baseline 0 0 0
4 hours 0 0 0
6 0.03 0.08 0.06
16 0.13 0.17 0.15
24 0.13 0.19 0.16
32 0.12 0.26 0.19
40 0.04 0.26 0.16
46 0.08 0.17 0.13
60 0.04 0.16 0.10
72 0 0.15 0.08
95 0 0.03 0.02
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OXFENDAZOLE
Oxfendazole [rrethyl 5 Cc]-phenylsulfinyl"2-benzimidazüle 
carbamate) is marketed in the United Kingdom as a suspension for 
oral use in cattle and sheep("Systamex”, Wellcomej "Synanthic”, 
Syntex).
Oxfendazole concentrations in the plasma of calves after 
oral dosage have been reported by Nerenberg, Runkel and Matin C1S7Ô), 
using a radioimmunoassay procedure developed by them. These 
authors found maximum concentrations of around 0.4 yg/ml occurring 
6-12 hours after administration of an oral dose of 3 mg/kg. No 
details as to the age or weight cf the calves, or whether or not 
they were pre-ruminant were given.
Prichard et al (1973), using the same assay, reported 
maximum plasma oxfendazole concentrations as high as 3.0 yg/ml in 
sheep dosed at 5 mg/kg occurring 24 hours after administration.
In this study oxfendazole was given orally at a dose 
rate of 10 mg/kg to six sheep in two separate experiments. The 
plasma, abomasa1 fluid and ruminai fluid concentrations of oxfendazole 
and the sulfone were measured at various times after dosing. In a 
number of plasma samples fenbendazole was also rmasured.
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MATERIALS AND METHODS
Initially the experiment was carried out on three sheep 
CM, S and B) but when oxfendazole was subsequently found to be 
present in the final sample (taken at 5 days) it was repeated in a 
further three sheep. In this group fewer samples were taken to 
minimise the analysis required, and an additional sample cf abomasal 
fluid was taken at ID minutes to assess possible reticular groove 
function.
Oxfendazole was administered in the form of a commercial 
suspension "Synanthlc", Syntex) containing 2.265% w/v suspension 
via a syringe placed on the back of the tongue.
The methods of sampling, storage and analysis have all 
been described in Chapter 2.
RESULTS
Plasma ana abomasal fluid concentrations of oxfendazole^and 
sulfone are shcvm in Table 5 (7) and the mean concentrations ere also 
represented in Figs. 5 (5) and 5 (7) respectively.
Ruminai fluid concentrations of oxfendazole are shown in 
Table 5 (8).
The maximum concentrations of oxfendazole and sulfone 
achieved both in plasma and abomasal fluid, and the length of time 
for which they were detectable, were extiwely variable in different 
sheep.
Mo oxfendazole was detected in plasma at 30 minutes after 
administration, demonstrating the relatively slow absorption of 
the drug. Maximum concentrations of 0.5-1,3 yg/ml occurred between
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Table 5 C7) Plasma and abomasal fluid concentrations of oxfendazole 
and oxfendazole sulfone after oral administration of 
oxfendazole (10 mg/kg) as a suspension
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Fig, 5 (B) Mean plasma concentrations Cyg/ml) of oxfendazole 
and oxfendazole sulfone in six sheep after oral 
administration of oxfendazole CIO mg/kg) as a 
suspension
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Fig. 5 (7) Mean abomasal fluid concentrations (yg/ml) of
oxfendazole and oxfendazole sulfone in six sheep 
after oral administration of oxfendazole (10 mg/kg) 
as a suspension
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TABLE 5 C8) RUMKJAL FLUID CONCENTRATIONS (yg/ml) DP OXFENDAZOLE
AFTER ORAL ADNI
AS A SUSPENSION
M NISTRATION OF OXFENDAZOLE (10 mg/kg)
Time
S h e e o n a m e
Mean ±. cLE.M.M S B E R G
Baseline 0 0 0 0 0 0 0
30 min - - - — — -
4 hours G.61 0.26 0.15 - - - 0.34 ± 0.14
8 0.55 0.22 0.28 - - - 0.35 ± 0.10
12 0.24 0.16 0.46 0.05 0.00 0.51 0.24 ± 0.09
16 0.43 0.08 0.39 - - - 0.30 ± 0.11
20 0.43 0.08 0.22 - - - 0.24 + 0.10
24 0.49 0.17 0.24 0.14 0.00 0.16 0.20 ± 0.07
30 0.34 0.08 0.25 — - - 0.22 + 0.08
36 0.27 0.07 0.24 - - - 0.19 ± 0.06
48 0.61 0.03 0.15 0.12 0.00 0.25 0.19 ± 0.09
72 0.24 0.07 0.16 0.08 0.00 0.18 0.12 ± 0.04
96 0.06 0.05 0.12 0.08 0.08 0.18 0.10 ± 0.02
5 days 0.21 0.05 0.09 0.53 0.00 0.09 0.16 ± 0.08
B “ - - 0.16 0.00 0.04 0.07 + 0.05
7 - - - 0.08 0.04 0.07 0.06 ± 0.01
8 - - - 0.18 0.00 0.08 0.09 ± 0.05
9 - - - 0.82 0.00 0.23 0.35 + 0.24
11 - - - 0.24 0.00 0.08 0.11 + 0.07
14 — — - 0.00 0.00 0.18 0.06 ± 0.06
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24 and 48 hours after dosing, and drug was detectable for up to 7 
days, Sulfone was present by 4-8 hours after administration and 
reached maximum concentrations by 48-72 hours. It was present in 
much lov/er amounts than oxfendazole. Oxfendazole was present in the 
aborrasal fluid by 10 minutes after dosing, and persisted for up to
9 days. Sulfone was detectable by 16-20 hours and was below the 
limit of detection by 5 days.
Ruminai fluid concentrations of oxfendazole v/ere remarkably 
low, the maximum in any of the six sheep being 0.6.yg/ml. The 
sulfone was not found in any of the ruminai fluid samples.
During the course of these experiments Nerenberg et al 
(1978) described the sulfide of oxfendazole (fenbendazole) as being 
one of the metabolites of oxfendazole found in the plasma of sheep 
treated with oxfendazole. (Evidence for this observation was not 
given).
Under the solvent conditions used routinely to measure 
oxfendazole, fenbendazole would have been detectable only at 
relatively high concentrations. A number of plasma samples were 
therefore re-assayed and the presence of fenbendazole confirmed. 
Subsequently two different sheep were dosed with oxfendazole at
10 mg/kg as in the previous experiments, and plasma oxfendazole and 
fenbendazole concentrations determined simultaneously. The results 
are given in Table 5 (9).
The concentrations of fenbendazole found at any time varied 
between 0 and 20% of those of oxfendazole present at that time.
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TABLE 5 C9) PLASMA CONCENTRATIONS Cyg/ml) CF OXFENCAZOLE AND
FENBENDAZOLE AFTER CRAL ADMINISTRATION OF OXFENDAZOLE
CIO mg/kg) AS A SUSPENSION
OXFENDAZOLE 
Sheép name
FENBENDAZOLE 
Sheeo naræ
.Time L fM Mean L N Mean
Baseline 0 0 0 0 0 0
G hours 0.43 0.60 0.62 0.04 0.07 0.06
12 0.79 1.37 1.03 0.18 0.18 0.13
IB 0.80 1.24 1.02 0.18 G.16 0.16
20 0.97 1.18 1.08 0.20 0.19 D.20
24 0.66 0.96 0.91 0.17 0.14 0.15
36 0.68 0.67 0,66 0.13 0.08 0.11
48 0.59 0.27 0.43 0.10 0.03 0.07
86 0.12 0.05 0.09 0.00 0 0.00
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ALBENDAZOLE
Albendazole, methyl (5-CprapylthicHLH-benzimidazül-2-yl) 
carbarrate, is available in the United Kingdom for use in sheep 
and cattle as an oral suspension ("Valbazen", Smith Kline Animal 
Health). In other European countries it is also marketed as a 
paste formulation.
Kinetic studies with albendazole hâve been made using 
radio-labelled albendazole (Dicuollo et al, 1977), In sheep 
given a single oral dose of 16 mg/kg, maximum plasma 
concentrations equivalent to 3.7 yg/ml of albendazole or related 
products [not distinguished) were found 15 hours after administration. 
In calves given 20 mg/kg, the peak concentrations were 5.5 yg/ml 
15-24 hours after treatment.
During the early part of this study plasma samples from 
ten lambs being used in an efficacy study of albendazole were assayed 
for the drug. No albendazole was detected in the plasma of any of 
these lambs dosed with 5 mg/kg, but high concentrations of a 
metabolite were present. Samples of the major metabolites of 
albendazole in sheep, the sulfoxide, the sulfone and the 2-amino 
sulfone [Fig. 5 (6)) v/ere obtained by gift from Smith Kline Animal 
Health Produots and concentrations of albendazole and these metabolites 
investigated in the experimental sheep.
Initially the study was perforr^d using commercial 
suspension "Valbazen" containing 2.5% w/v of albendazole.
On completion of the study using albendazole suspension.
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Fig. 5 C8) The structures of albendazole and its major metabolites
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the question arose as to whether the kinetics of albendazole when 
delivered as a paste formulation were similar to those after the 
suspension. This was of considerable commercial interest to Smith 
Kline, since regulatory authorities in other E.E.C. countries were 
questioning whether the considerable volume of efficacy data obtained 
using the suspension formulation could be translated to the paste.
To investigate this problem the study was repeated using the 
same experimental design, with the drug being given as a paste.
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MATERIALS AND METHODS
The sarm sheep B, S, G, were used for both the paste and 
the suspension trials which were carried out 2 months apart. In both 
cases the dose rate was 10 mg/kg, the drug being given via a syringe 
placed on the back of the tongue. The paste was supplied by Smith 
Kline Animal Health (Lot No. 12/78 ko3) and contained 30% w/v 
aIbendazole,
Samples of plasma, abomasal fluid and ruminai fluid were 
taken prior to drug administration and at 4, 8, 12, 16, 20, 24, 32,
48, 72, 98 hours and 5, 7, 8 and 11 days after administration. 
Additional abomasal fluid samples were taken at 10 minutes (suspen­
sion) and 10 minutes and 30 minutes (paste).
Sarrples were taken, stored and analysed for albendazole, 
albendazole sulfoxide and albendazole sulfone as described in 
Chapter 2.
RESULTS
The concentrations of albendazole, sulfoxide and sulfone 
in plasma and abomasal fluid after the administration of albendazole 
suspension are shown in Tables 5 (10) and 5 (11). Ruminai fluid 
concentrations of albendazole are given in Table 5 (12). The 
sulfoxide and sulfone could not be detected in rumen fluid following 
either paste or suspension treatment.
Tables 5 (13), 5 (14) and 5 (15) show plasma and abomasal 
fluid concentrations of albendazole, the sulfoxide and sulfone, and 
ruminai fluid concentrations of albendazole, after albendazole paste 
administration.
138
g
i
E
!
□
LU
C/l
I
I
-3
I
n (O CD c o CO e n
CD O r-t CD CD o
CD o CD CD CD CD
•H -H +4 ■M -H ■H
r - . (O CM e n e n es.
CD r-# m en IS. IS .
CD CD CD CD O CD
m < r v n en c o in
CD m a LO CD en
CD CD CD CD CD CD
-H M •H -H ■H ■H
e n tn e n CO en
e n CJ) f—4 c o
CM CM CM e n CM
CD o
o CD
■H 4L O CD CD CD
CM
CD CD
CD CD
en CO en M - CM
1—1 to
O
CD CD CD CD CD
CM
a
-H
a
o
c o
O
o
c o
O
-H
(O
O  O
C3
e o c o CM (M e n CD e n
CD CM < - c o lO
CD CD CD CD CD CD CD CD
ë
I
m CO t—4 en CM en tn
CD CM in to eo c o 03 CD
CD CD CD O CD CD CD CD
s
<=f
il
î i
ùû<
X S
O l m to tn
e n CM e o CD e o e n CD
CM CM e n CM CM
O
o
( 3
a
CD
O
O
R
o
ll
c  CD
I
I
CD
CD
5:
%
I
I—  w O
(N
(M(n
I
139
I
'k
I
LU
C/Î
4)
C
□
s
m CO cn cn CO CM CM(M n CO 4J» CO to CM in 4M
o O Q a CD o CM O Q
o +1 44 41 41 44 44 44
o CO 4M m cn cn O<r CM CO CO cn M" CM rs.
o r-1 CM cn f 1-i o
cn 4M CM to in in 04 to nto in CM CN 4M 1—4 rsj rstotn tn <r CO CO to *—i a
o +4 44 44 44 44 41 44 44 44 +t
cn Q O rx in cn 4M tn rs. cnCO m O cn CM cn cn m CM rs
to CO m to CM 04 CM oCM CM CM CM CM
w in cn CO to in in 4M f>j r-tm CM CD 4M M- M- CD to CD o o
1—1 CM CM CM CM "-4 CD CD o d
-H 44 44 41 44 44 44 44 44 44 •H
1 t oi cn ,— j 4M CD to CO fO 1CM cn CM o in cn 1—4 Q a
M- in CO CM CM CD a o
m CO r-H CO CD 04 04 O) □sr cn to n- CD r-4 CMQ O o O CD CD (N
o CD O) o COCO L3 in Csl cn CO CN cn
o a CN tn cn
CO rs CN 4—t (N a CN cncn cn cn CO in cn O rs
CD CN cn cn cn N" CN
«=r rO CN cn CO (N CN Olo to m CD
cn 2 cn to CO CD cn CNCN *—1
CD GO O) a CTÏ rsCN CN «;r CO CO in CN
in CO tn rN in CD CN N-r-A CN m m Ol to CN
E O
s ^  
| :
cn a
iî
O CN CN 01 (N CO rsfs CO cn 1—i to rs tn
CN cn O sr O =3 cn
CN CN rN r-l
cn CD to m cn fs COlO fs Osl o cn 2 1—t
CO (N a
ro
(N
o
CM
fN
(N
d
m
LU
tom
E
o CMm
I
140
TABLE 5 [12) RUMEN CONCENTRATIONS [yg/ml] OF ALEENDAZCLE AFTER 
ORAL ADMINISTRATION OF ALEENDAZOLE (10 mg/kg) AS A 
SUSPENSION
Time B
Sheep Narre 
S G Mean ± S.E.M.
Baseline 0 0 0 0
4 hours 0.72 1.31 1.77 1.27 ± 0.31
8 0.69 1.21 N. S. 0.95 ± 0.26
12 0.69 1.76 1.19 1.21 ± 0.31
IB 0.51 1.10 1.68 1.10 ± 0.33
20 0.66 0.53 1.50 0.90 ± 0.31
24 0.38 0.50 1.07 0.65 ± 0.21
32 0.17 0.24 0.66 0.36 ± 0.16
48 0.05 • 0.05 0.19 0.10 ± 0.05
72 0.02 0 0.04 0.02 ± 0.01
96 0 0 0 0
5 days 0 0 0 0
7 0 0 0 0
8 0 0 0 Ü
11 0 0 0 0
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TABLE 5 (151 RUMEN CONCENTRATIONS (pg/ml) OF ALBENDAZOLE AFTER
ORAL ADMINISTRATION (10 mg/kg1 OF ALBENDAZOLE AS A PASTE
Tirre B
Sheep Name 
S G Mean ± S.E.M.
Baseline .0 0 0 0
4 hours 1.11 1.07 1.04 1.07 ± 0.02
6 0.70 0.92 1.15 0.92 ± 0.13
12 0.65 0.59 0.81 0.68 ± 0.06
16 0.60 0.51 0.61 0.57 ± 0.33
20 0.39 0.51 0.56 0.49 ± 0.05
24 0.76 0.26 0.36 0.46 ± 0.15
32 0.20 0.17 0.33 0.23 ± 0.04
46 0.06 0.03 0.17 0.11 ± 0.03
72 0.03 0.02 0.04 0.03 ± 0.01
96 0.03 0 0.03 0.02 ± 0.01
5 days 0 0 0 0
7 0 0 0 □
6 0 0 0 D
11 0 0 0 0
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Mean plasra and abomasal fluid concentrations of 
albendazole, sulfoxide and sulfone after suspension and paste 
formulations are also represented in Figs. 5 C9) and 5 (10) and 
5 (113 and 5 (123 respectively.
Plasma albendazole concentrations were below the limit 
of detection at all tirres in one animal and the drug was present 
only at very low concentration and only for a short time in the 
other two sheep. Similar results were obtained with both 
formulations of the drug.
Albendazole sulfoxide was detectable in plasma by 4 hours 
after treatment, and maximum concentrations were achieved by 16-20 
hours in most cases. The sulfone was also detectable by 4 hours 
but maximum plasma concentrations of this metabolite occurred 
somev/hat later, at around 32-46 hours after drug administration.
Albendazole was present in the abomasal fluid of all 
three sheep by ID minutes after administration of both suspension 
and paste formulations, vjith maximum concentrations occurring at 
4-12 houre.
The sulfoxide was not present in any of the 10 minute 
samples, but by 4 hours had reached high concentration in abomasal ■ 
fluid. In all animals with both formulations of albendazole, the 
peak sulfoxide concentrations in abomasal fluid v/ere greater than 
those of the parent drug. Maximum sulfoxide concentrations were 
measured at 16-20 hours, and the metabolite was below the detectable 
limit by 3-5 days.
Albendazole sulfone was present in abomasal fluid by 4-6
145
hours. Maximum concentrations were lower than those of albendazole 
and the sulfoxide and, as in plasma, occurred later than those of 
sulfoxide, at 32-48 hours.
Rumen fluid concentrations of albendazole were generally 
below 1 pg/ml, the highest concentration found at any time being 
1,6 yg/ml. Drug persisted for 3-4 days.
The concentrations of albendazole, the sulfoxide and the 
sulfone in plasma, ruminai fluid and abomasal fluid after administration oi 
paste and suspension formulations were tested for significant 
differences, using the Student t-test for paired samples. Only 
at one time were the albendazole concentrations significantly 
different at the 5% level [48 hours in the abomasum), and at no tirrn 
the sulfoxide or sulfone concentrations.
Since values were compared at sixteen different times, it 
may be that this significant difference at 48 hours in the abomasum 
was the result of chance.
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Fig. 5 (9) Mean plasma concentrations [yg/ml) of albendazole,
albendazole sulfoxide and albendazole sulfone in three 
sheep after oral administration of albendazole [10 mg/kg) 
as a suspension
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Fig. 5 CIO) Mean aborrasal fluid concentrations (yg/ml) of albendazole, 
albendazole sulfoxide and albendazole sulfone in three 
sheep after oral administration of albendazole (10 mg/kg) 
as a suspension
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Fig. 5 Cil) Mean plasma concentrations Cug/ml) of albendazole,
albendazole sulfoxide and albendazole sulfone in three 
sheep after oral administration of albendazole CIO mg/kgj 
as a paste
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Fig. 5 [12] Mean abomasal fluid concentrations Cyg/ml) of
albendazole, albendazole sulfoxide and albendazole 
sulfone in three sheep after oral administration 
of albendazole (ID mg/kg) as a paste
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INVESTIGATION OF THE SITE OF METABOLISM OF EENZIMIÜAZOLE DRUGS
The site of metabolism of the benzimidazoles was of obvious 
importance because of the high concentration of metabolites found 
in these experiments.
Most drug metabolism in mammalian species is carried out 
by the hepatic microsomal enzyme systems, one of the most important 
groups of enzymes in this respect being the mixed function oxidases. 
These enzymes catalyse many drug transformations, including sulfoxide 
formation (Goodman and Gilman, 1975), Such drug transformations 
involve the reduction of cytochrome P-450, a component of the 
mixed function oxidase system, by NADPH. The reduced form of 
cytochrome P-450 together with molecular oxygen reacts with the 
substrate (drug) to form oxidised drug with regeneration of the 
oxidised form of cytochrome P-450.
Drug metabolism also occurs in the gastro-intestinal tract; 
microflora of the gut including those of the rumen are capable of 
certain drug transformations. Chloramphenicol, for example, is 
reduced by ruminai microflora (Theodorides et al, 1968; De Corte 
Baeten and Debackere, 1978), and Nielson et al (1978) have shown 
trimethoprim to be extensively degraded in the functional rumen.
Circumstantial evidence from the concentrations of 
metabolites in the various body compartments suggested that the 
liver rather than ruminai micro-organisms was involved in 
benzimidazole metabolism. Although high concentrations of 
metabolites, particularly sulfoxides, were found in plasma (and 
abomasal fluid) after oral administration of parent drug, these
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metabolites were not detected in ruminai fluid. The presence of 
oxfendazole in plasma after intra-abomasa1 administration of 
fenbendazole also suggested that the rumen was not the site of 
conversion. For this to be the case fenbendazole would require to 
be absorbed from the abomasum/small intestine, diffuse back into the 
rumen, undergo metabolism and the oxfendazole be reabsorbed. Neither 
fenbendazole or oxfendazole were detected in the rumen fluid of 
these animals.
One further consideration is that conditions within the 
normal reticulo-rumen strongly favour reduction reactions CBroberg, 
1957). Sulfide conversion to sulfoxide and sulfone is in both 
cases an oxidation, which is more likely to be liver associated.
In order to investigate the site of metabolism of these 
drugs more closely, albendazole, albendazole sulfoxide, fenbendazole 
and oxfendazole were incubated separately with sheep ruminai fluid 
and abomasal fluid and with a bovine hepatic microsomal preparation. 
Samples were taken at intervals and assayed for drug and metabolites.
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MATERIALS AND METHODS
Ruminai and abomasal fluid
The procedure v^ as similar for each drug. Fresh ruminai 
and abomasal fluid was collected from three sheep, centrifuged, 
and the supernatant fluid filtered through coarse filter paper 
(Whatman No. 4). The samples of each fluid were pooled and divided 
into 25 ml aliquots (measuring cylinder). To these were added 
15 pi (Eppendorf) of the appropriate cormarcial suspension "Panacur" 
2.5%" (Hoechst U.K. Ltd), "Valbazen 2.5%" (Smith Kline Animal Health 
Ltd) and "Synanthic" (Syntex) containing 2.265% v//v oxfendazole, to 
give a concentration of about 15 pg/ml. In the absence of a 
commercial preparation of albendazole sulfoxide, the pure substance 
as supplied by Smith Kline Animal Health Products was used. Because 
of the insolubility of this compound in aqueous fluids, and the 
difficulty of producing a homogeneous aqueous suspension the 
required final concentration of 15 yg/ml was achieved by adding 
3.75 ml of a solution of albendazole sulfoxide(100 yg/ml)in absolute 
alcohol to a 50 ml beaker. The alcohol was evaporated to dryness,
1 ml of water added to the residue and the beaker sonicated for 5 
minutes, 24 ml of blank rumen fluid or abomasal fluid were then 
added. 25 ml aliquots of blank ruminai fluid and abomasal fluid 
and of the appropriate drug in phosphate buffer (pH 6) v/ere prepared 
at the same time as controls,
A 5 ml aliquot of each fortified sample and of each control 
sample was removed and immediately deep frozen (-20°C). The 
remainder was transferred to 50 ml glass conical flasks connected to
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a source of carbon dioxide. The flasks vvei'e incubated in a shaking 
water bath for 24 hours at a constant temperature of 39°C under a 
continuous flow of carbon dioxide.
At intervals the flasks v/ere removed and, after correcting 
the volume for evaporation with warm distilled water, 5 ml aliquots 
were removed and frozen.
The samples were later thawed, extracted and assayed for 
parent drug and metabolites.
Bovine hepatic microsomes
Preparation of bovine hepatic microsomes for incubation 
was carried out with the assistance of Mr, Hanafy, Department of 
Veterinary Pharmacology, by the following method:
Liver tissue from three freshly killed 6-12 month old Ayrshire 
calves was chopped with scissors and excess connective tissue 
removed. The tissue (50 g) was homogenised in four volumes of ice- 
cold media composed of D.154M Kcl and Ü.Ü5M Tris-Hcl buffer (pH 7,4) 
in an Atomix blender (MSB Ltd) for 2 minutes. The homogenised 
material was strained through gauze and centrifuged at 16,000 xg 
for 20 minutes. The 16,000 xg supernatant was decanted into 
ultracentrifuge tubes and centrifuged at 105,000 xg for 60 minutes 
(Beckman L2-65B ultracentrifuge with type 50.1 rotor). The 
resultant microsomal pellets were re-homogenised in phosphate buffer 
pH 7.4.
Each incubated sample contained, in a volume of 1.5 ml 
phosphate buffer (pH 7,4), 4 mg of microsomal protein, 8.5 rng of 
NADP, 63 mg of glucose-6-phosphate and 2 units of glucose-6-phosphate
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dehydrogenase as an NADPH generating system. To this, the 
appropriate drug was added as substrate.
A similar preparation with boiled (10 minutes) microsomes 
was used as a central, and each drug was also incubated in the 
equivalent volume of phosphate buffer (pH 7.4) with cofactors.
Because of the impossibility of preparing an aqueous 
solution, or a homogeneous aqueous suspension of these drugs, no 
attempt was made at quantitative measurement of conversion. The 
drugs were added as 0,5 ml of a suspension of pure drug in pH 7.4 
buffer.
The fresh and control preparations were then incubated in 
open test tubes in a shaking water bath at a constant temperature of 
39°C. A 1 ml aliquot of each was removed after 3 hours and the 
remainder after 6 hours. These were deep frozen and assayed the 
following day after thawing for parent drug and metabolites.
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RESULTS
Ruminai and abomasal fluid
No metabolites vjera detected in samples assayed after 
incubation of albendazole and fenbendazole with either ruminai or 
abomasal fluid, nor was there any decrease in concentration of the 
parent drug over the 24 hour incubation period.
Incubation of oxfendazole with ruminai fluid resulted in 
the appearance of a chromatographic peak which had a retention tine 
exactly similar to that of fenbendazole. The relative concentrations 
of oxfendazole and fenbendazole are shown in Table 5 (16). This 
metabolite was not found after incubation with abomasal fluid.
Similarly incubation of albendazole sulfoxide with
ruminai fluid but not abomasal fluid resulted in the appearance of
a peak on the chromatogram with a retention time exactly similar to 
that of albendazole. The relative concentrations of albendazole
and its sulfoxide are shown in Table 5 (17).
None of the control incubations gave rise to any 
detectable metabolite formation.
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TABLE 5 (16) CONCENTRATION OF OXFENDAZOLE AND FENBENDAZOLE AFTER 
INCUBATION OF OXFENDAZOLE WITH RüMINAL FLUID
Concentration yg/ml)
Time Oxfencazole Fenbendazole
Pre-incubation 14.40 (100) G (0)
4 hours 14.23 (98.2) 0.25 (1.8)
8 hours 13.97 (97.2) 0.40 (2.8)
24 hours 13.24 (91.2) 1.27 (8.6)
Figures in parenthesis represent concentration as a
percentage of total.
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TABLE 5 C17) CONCENTRATION OF ALBENDAZOLE SULFOXIDE AND ALBENDAZOLE 
AFTER INCUBATION OF ALBENDAZOLE SULFOXIDE WITH RUMIr.AL 
FLUID
Concentration yg/ml
Time Albendazole sulfoxide Albendazole
Pre-incubation 14.60 (1)) 0 (0)
4 hours 14.61 (100) 0 (□)
8 hours 14.79 (99.9) 0.02 (0.1)
24 houra 14.41 (88.9) 1.80 (11.1)
Figures in parenthesis represent concentration as a
percentage of total.
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Bovins hepatic microsomes
Incubation of both albendazole and fenbendazole with fresh 
bovine hepatic microsomes resulted in the production of a metabolite 
with an exactly similar retention tirre under HPLC to that of the 
respective sulfoxide and sulfone. When the extracts were re-injected 
under the methanol/perchloric acid solvent routinely used to separate 
these metabolites both metabolites were found to be present.
The relative concentrations of fenbendazole, oxfendazole 
and sulfone, and of albendazole, sulfoxide and sulfone are shown in 
Tables 5 (18) and 5 (19).
Sulfoxide incubation with microsome preparations in both 
cases resulted in formation of small amounts of albendazole and 
fenbendazole respectively as well as albendazole end fenbendazole 
sulfones. (Tables 5 (20) and 5 (21)).
There was slight conversion with the boiled microsomal 
preparations from sulfides to sulfoxides and sulfones, but no 
apparent reduction of sulfoxides to sulfides. No conversion occurred 
when the drugs were incubated with buffer + co-factors.
The results show that the in vivo metabolism of the three 
benzimidazole drugs studied was due to the activity of liver 
microsomes and not to gastro-intestinal micro-organisms. Metabolism 
by similar oxidation enzyme systems might also have occurred to 
some extent in other organs, particularly the lung and kidneys, but 
almost certainly the contribution of these sites to the overall 
conversion would be small conpared with that of the liver.
Because of the difficulties caused by the aqueous
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insolubility of these drugs and also because a detailed study of 
their metabolism was outwith the main theme of this thesis, no further 
attempt was made to measure rates of conversion or to identify properly 
the enzyme system involved.
The apparent reduction of sulfoxide to sulfide was
surprising; reduction reactions of this type are uncormnon in the
liver and, since from these studies it appeared that the oxidation 
reaction was occurring at a much faster rate than the reduction, it 
was difficult to understand why the sulfide v/as detectable at all.
The sulfide v;as not formed during the extraction procedure as was
evidenced by failure to detect sulfide in those incubations with all 
the components present, with the exception of microsorres. The 
sulfide metabolite was identified purely on the basis of its 
chromatographic characteristics under tw'o HPLC solvent systems, 
and therefore could not be regarded as beyond dispute.
The occurrence of both oxidation and reduction reactions 
simultaneously was confirmed, however, by a subsequent report 
describing the incubation of both fenbendazole and albendazole with 
mouse liver enzymes (Douch and Buchanan, 1979). These authors found 
sulfoxide formation and sulfoxide reduction to occur in the microsomal 
fraction of mouse liver with both fenbendazole and albendazole and 
determined the optimal conditions for each enzyræ activity. Non- 
emzymic oxidation of fenbendazole, but not albendazole, was also 
reported; this non-enzymic oxidation may explain the sulfoxide 
formation found in this study during incubation with boiled microsomes. 
This had previously been thought to be due to failure to denature
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completely the microsomal enzymes by the boiling procedure. (The 
'boiled' samples were placed in test tubes in a boiling water bath 
and in the 10 minute boiling period may not have attained 100°C3.
A further demonstration of the reversibility of the sulfide-sulfoxide 
reaction has recently been found with the unrelated drug sulindac, a 
non-steroidal anti-inflammatory drug CDuggan, Hooke and Hwang, 1960). 
Irreversible oxidation of sulfoxide to sulfone also occurs. When 
different radio-active labels were attached to sulfoxide (^^C-label)
3
and sulfide C H-label), and both drugs administered simultaneously by 
intravenous injection to rats and guinea pigs, these authors found 
an extremely rapid equilibration of both labels among the three forms 
of the drug.
161
TABLE 5 Clô) congé:iTRATIBN OF FENBENDAZOLE, ÜXFENDAZOLE AND SULFO.XE 
AFTER IfiCUBATIü:-j OF FENBENDAZOLE WITH BOVINE HEPATIC 
HICROSOMES
C o n c e n t r a t i o n  (ug/ml)
Fresh micmsoires Boiled microsorres
Time Fenbendazole Gxfendazole Suifone Fenbendazols Gxfendazole Suifon?
3 hours 1Ü.7BC7B.9) 2.95C21.1] 0.28(2.0) 19.76(97.1) 0.60(2.9) 0
6 hours 10.37(74.1) 3.57(25.5) 0.34(2.4) 16.29(99.3) 0.13(0.7) 0
Figures in parenthesis represent concentration as a percentage of total.
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TABLE 5 C19) CONCENTRATION OF ALBENDAZOLE, ALBENDAZOLE SULFOXIDE A.-.D 
ALBENDAZOLE SULFONE AFTER INCUBATION OF ALBENDAZOLE WITH
BOVINE HEPATIC MICROSOMES
C o n c B 
Fresh microsonr.es
n t r a t i o n  (yg/ml)
Boiled microsomes
Time Albendazole Sulfoxide Sulfone Albendazole Sulfoxide Sulfone
3 hours 29.36(44.4) 33.55(50,7) 3,20(4.6) 27.05(98.4) 0.45(1.6) 0
6 hours 25.74(41.2) 33.55(53.7) 3.20(5.1) 25,04(98.7) 0.32(1.3) 0
Figures in parenthesis represent concentration as a percentage of total.
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TABLE 5 (20] CONCENTRATION OF FENEENDA2QLE, OXFENDAZOLE AND SULFONE 
AFTER INCUBATION OF OXFENDAZOLE WITH BOVINE HEPATIC
MICROSOMES
C o n c e n 
Fresh microsomes
t r a t i 0 n (pg/ml)
Boiled microsomes
Time Fenbendazole Oxfendazole Sulfone Fenbendazole Oxfendazole Sulfone
3 hours 1.67(4,2) 36.66(92.1) 1.48(3.7) 0 23.05(96.6) 0.8(3.4)
6 hours 0,51(1.27) 38.01(94.7) 1.60(4.0) 0 25.20(96.9) 0.8(3.1)
Figures in parenthesis represent concentration as percentage of total.
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table 5 C21) CONCENTRATION OF ALBENDAZOLE, ALBENDAZOLE SULFOXIDE AND 
ALBENDAZOLE SULFONE AFTER INCUBATION OF ALBENDAZOLE 
SULFOXIDE WITH BOVINE HEPATIC MICROSOMES
Fresh
C o n c e n t r â t  
1 microsorms
i o n  (pg/ml)
Boiled microsomes
Time Albendazole Sulfoxide Sulfone Albendazole Sulfoxide Sulfone
3 hours 0.16(5.6) 2.61(90.9) 0.10(.35) NS NS NS
B hours 0.04(1.5) 2.47(95.4) 0.08(3,1) 0 1.69(100) 0
Figures in parenthesis represent concentration as a percentage of total.
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THE EFFICACY OF ALBENDAZOLE AND ITS TVIQ MAJOR METABOLITES AGAINST 
MIPPOSTRONGYLUS ERAZILIENSIS IN THE RAT
The aim of this experiment was to compare the anthelmintic 
activity of albendazole sulfoxide and albendazole sulfone with that 
of albendazole itself. The three compounds were administered in 
feed to rats experimentally infected with third stage larvae of 
Nippostrongylus braziliensis and the worm burdens compared at 
slaughter.
Since in vivo metabolism of albendazole to the sulfoxide end 
sulfone might be expected to occur in rats as in sheep, making it 
impossible to assess the anthelmintic activity of albendazole per se, 
it was decided also, in one group of rats, to inhibit this metabolism 
by the use of a hepatic microsomal enzyme inhibitor. The compound 
chosen for this purpose was piperonyl butoxide which has been shown 
to inhibit hepatic microsomal drug metabolism in vivo and in vitro 
(Anders, 1968),
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MATERIALS AND METHODS
Thirty male rats (hooded Wistar strain) weighing between 16G 
and 210 g were each inoculated subcutaneously with 4,000 third stage 
N . braziliensis larvae on day 0. The rats were randomly divided 
into five groups of six rats. The groups were treated as follov/s:
Group 1) - Control group, fed normal ration.
Group 2) ~ Treated with albendazole in feed at 100 ppm from day
6 to day 9,
Group 3) - Treated with albendazole sulfoxide in feed at ICO ppm
from day B to day 9,
Group 4) " Treated with albendazole sulfone in feed at 100 ppm
from day 6 to day 9,
Group 5) - Treated with albendazole in feed at 100 ppm from:
day 6 to day 10, and were injected intra-peritoneally 
with piperonyl butoxide 500 mg/kg at 12 hour 
intervals beginning 2 hours before the medicated feed 
was offered.
All the rats were killed on day 10. Blood was taken into heparinised 
syringes at killing; the plasma was separated and frozen (-20°C). 
Analysis for albendazole and its metabolites was performed later.
Preparation of the feed
Commercial rat pelleted diet was ground to a fine powder
in an automatic grinder, 0,04 g of pure test compound was
accurately weighed and well mixed with a small quantity of ground
feed. Sufficient feed was added to bring the total weight to 400 g.
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and the feed mixed thoroughly. Sufficient water was added to form 
a damjD rrash and the mixture was re-pelleted using a 5 ml syringe.
The pellets were dried on top of a warm oven and stored at -20°C 
until required.
It would seem reasonable to assume that the heavier rats 
in each group would have a greater food intake than the smaller ones, 
and would therefore receive a proportionately greater amount of 
drug. The average dose then would be 6.67 mg per rat (33 mg/kg).
Estimation of worm burden
The counts of the worm burden of the rats were kindly 
undertaken by Mr. K. Bairden of the Department of Veterinary 
Parasitology,
RESULTS
When the experiment was designed it was calculated that 
the medicated feed would be sufficient feed from day 6 to killing on 
day ID. However groups 2, 3 and 4 had consumed all the medicated 
feed by the beginning of day 9, and normal ration was then fed. By 
day 8 after infection it was apparent that the rats receiving the 
piperonyl butoxide injections had a lower feed intake than the nonr 
injected groups, and also were diarrhoeic. Because of this the 
injections were discontinued after the morning of day 8. Partial 
recovery of appetite occurred but these rats consumed only 157 g of 
feed over 4 days compared with 400 g over 3 days taken by the other 
treated groups (mean dcse 12.6 mg/kg or 3.2 mg/kg/day for 4 days 
compared with 33 mg/kg or 11 mg/kg/day for 3 days).
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The worm burden of each rat, the group ir^ an and the 
percentage reduction conpared with controls are shown in Table 5 (22) 
The results demonstrate that albendazole sulfoxide has 
similar anthelmintic activity to albendazole and that albendazole 
sulfone has little or no anthelmintic activity. The low doses 
received by the liver enzyme inhibited group, together with the 
wide variation in worm burden within the group, makes it impossible 
to draw any conclusions as to whether metabolism of albendazole to 
the sulfoxide is necessary for good anthelmintic activity.
The volume of plasma obtained per rat varied from 0.5 ml 
to 4 ml. The majority, however, yielded >3 ml.
No albendazole or its sulfoxide or sulfone was detected 
in any of the samples. This was probably due to the fact that 30 
hours elapsed from the ingestion of the last of the drug until 
killing, except in the case. ,of Group 5 which had a vary low feed 
intake at this time.
In order to try and overcome the problems encountered with 
the repeated injection of piperonyl butoxide this part of the 
experiment was repeated using chloramphenicol as the microsomal 
enzyme inhibitor.
The effect of a single oral dose of 33.3 mg/kg albendazole 
was also studied.
MATERIALS AND METHODS
Twenty-five rats were infected and divided into four groups 
of six as in the previous experiment. The groups were treated as 
follows:
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TABLE 5 C22} RAT WORM BURDENS, GROUP MEAN AND REDUCTION AS PERCENTAGE 
OF CONTROLS AFTER TREATMENT
Treatment
R
1
a t
2
w o..r 
3
m
4
b u r
5
d e n
6 Mean
%age
Reduct­
ion
None-controls 1650 950 1190 1790 780 1660 1337
Albendazole IGDppm 0 0 0 0 0 0 0 100
Sulfoxide 100ppm 10 0 0 0 0 10 3 98.8
Sulfone lOOppm 1190 1740 1430 1630 1480 1020 1415 0
Albendazole lODppm + 
piperonyl butoxide 0 182D 70 1880 2360 30 1026 .23.3
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Group 1) - Controls, fed normal ration.
Group 2) " Albendazole in feed at 100 ppm from day 6 to day 9,
Group 3) - Albendazole at 100 ppm + chloramphenicol at 360
ppm in feed frarn day 6 to day 9. This group received 
feed containing chloramphenicol only for 12 hours 
preceding that incorporating albendazole.
Group 4) - A single oral dose of albendazole (33 mg/kg) given
to each rat.
The preparation of feed, infection and killing of rats and 
counting of the worms were all undertaken as in the previous 
experiment. The single dose was administered as pure drug in a 
gelatin capsule, and the rat held until the drug was swallowed. Plasma 
samples were not taken.
RESULTS
The results are shewn in Table 5 (23).
The poor larval ‘take’ with resultant low worm 
burdens in the control animals make the results difficult to 
interpret. It can be seen, however, that five out of six rats given 
the microsomal enzyme inhibitor had some adult worms at killing 
whereas albendazole was 100% effective in the non-inhibited group.
It can also be seen that the divided dose was more efficacious than 
a single oral dose of the drug.
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TABLE 5 (233 RAT WORM EL'RDENS, GROUP MEAN AND REDUCTION AS PERCENTAGE 
OF CONTROLS AFTER TREATMENT
Treatment
R a
1
t
2
w 0 r 
3
m b 
4
u r d 
5
e n 
6 Mean
%age
Reduct­
ion
None-controls 310 610 730 440 90 450 438
Albendazole lODppm 0 0 0 0 0 0 0 100
Albendazole lODppm + 
chloramphen­
icol 360ppm 10 □ 20 10 20 10 12 97.3
Single oral 
dose 33 mg/kg 30 0 40 0 0 20 15 96.6
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□ne further experiment was undertaken in rats, namely the 
administration of a single oral dose of albendazole, with sequential 
blood sanples to establish whether absorption and metabolism of 
albendazole in rats was similar to that seen in sheep.
MATERIALS AND METHODS
Twelve adult rats were weighed and dosed with Valbazen 
2,5% suspension at a dose rate of 33 mg/kg (0.13 ml per 100 g]. At 
times 1, 4, B and 24 hours post dosing groups of three rats were 
killed, and bled. (These times were chosen after examination of the 
results of an earlier study in another monogastric animal, the dog 
(unpublished), in which it was found that maximum plasma concentrations 
of albendazole and its metabolites were achieved 2 hours after oral 
administration of albendazole). The plasma from the three rats 
was pooled and assayed for albendazole and its metabolites,
RESULTS
The plasma concentrations of albendazole, sulfoxide and 
sulfone are as shown in Table 5 (24), These results demonstrate 
that the metabolic pathway in rats in similar to that in sheep. One
interesting difference is that plasma concentrations of albendazole- 
itself are higher in rats than in sheep.
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TABLE 5 (24) MEAN PLASMA CONCENTRATION (pg/ml] OF ALBENDAZOLE, 
ALBENDAZOLE SULFOXIDE AND ALBENDAZOLE SULFONE IN 
3 RATS GIVEN ALBENDAZOLE AT A DOSE RATE OF 33 mg/kg
Time of 
killing
Albendazole 
(pg/ml}
Albendazole
sulfoxide
(pg/ml)
Albendazole
sulfone
(pg/ml)
1 hour 0.31 0.53 0.54
4 hours 0.42 2.53 0.70
8 hours 0.16 1.69 0.73
24 hours 0.01 0 0
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DISCUSSION
□ne of the most striking features of the kinetics of the 
three benzimidazole drugs studied is the length of time for which 
they and their metabolites were detected both in plasma and in the gut 
after a single oral dose. Oxfendazole, for example, was present in 
abomasal fluid for 9 days and in plasma for 7 days in one animal 
after oral administration of the drug.
If duration of activity is important in determining the 
efficacy of these drugs, then the rumen may play a crucial role in 
explaining the greater potency and efficacy seen in ruminant animals 
compared with monogastric animals. The studies in rats, and also 
work in the dog (unpublished) demonstrate that plasma concentrations 
of albendazole and its metabolites in these species are relatively 
very low by 24 hours after administration of doses 2-3 times greater 
than those given to the sheep in these experiments.
Concentrations of the three benzim.idazoles and their 
metabolites in plasma and gastro-intestinal fluid varied greatly in 
individual animals and this was especially true of ruminai fluid 
concentrations. Dissolved ruminai fluid concentrations of oxfendazole 
were markedly lower than those of albendazole or fenbendazole, perhaps 
reflecting a lower aqueous solubility of oxfendazole.
One obvious feature of all three drugs is that the 
concentrations in ruminai fluid did not approach the theoretical 
maximum (circa 50 yg/ml) expected if the total dose was delivered to 
the rumen and dissolved. It is almost certain that the slow 
kinetics of these drugs demonstrated in this study are a result of 
their extremely low solubility in aqueous fluids. Even albendazole
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which, of the three drugs investigated, had the most rapid kinetics, 
persisted in ruminai fluid for 3 days, confirming the view that the 
rumen acts as a "reservoir" of slowly dissolving drug which then 
becomes available for absorption. No data are available on the
solubility of these three drugs. The closely related benzimidazole,
mebendazole, has a quoted solubility of <50 pg/ml in water (Kelly, 
Chevis and Goodman, 1975).
Since abomasal fluid concentrations of these drugs, 
particularly oxfendazole and albendazole, were higher than those of 
ruminai fluid at the equivalent time, it is probable that some 
undissolved drug reached the abomasum. The lower pH of this part 
of the gut would be expected to result in higher dissolved 
concentrations of these basic drugs. Passive diffusion of 
benzimidazole from the systemic compartment in theory may also have 
contributed to the higher dissolved abomasal fluid concentrations. 
However the low plasma albendazole concentrations seen in all 
animals make this mechanism unlikely to be significant for this 
drug. Careful examination of the results also reveals that the 
ratio of concentration of oxfendazole in abomasal fluid to that in 
plasma after fenbendazole administration (where abomasal fluid 
concentrations must have resulted entirely from passive diffusion 
from the plasma) was much lower than that seen after administration 
of oxfendazole itself.
Dissolved drug may have passed on from the rumen during the 
process of normal rumen errptying or may have been deposited in the 
OfTBsum by the action of the reticular groove during dosing, and
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subsequently reached the abomasum. On each occasion when sheep 
were dosed, irrespective of which drug or formulation was given, 
all animals were found to have drug in the abomasum by 10 minutes 
after oral administration. The concentrations found were highly 
variable and their significance is difficult to assess. It was not 
always the case that animals which had high concentrations of drug 
in the abomasal fluid at 10 minutes had lower or less persistent 
plasma or abomasal fluid concentrations of drug or metabolites.
The current view that the rumen provides a slow release 
reservoir of benzimidazole has led to the suggestion that ruminai 
by-pass of these drugs via the reticular groove at dosing may be 
one reason for the occasional anthelmintic failures which have been 
reported (Lancaster and Hong, 1377),
These results do not actively support this hypothesis.
In this small number of animals rumen by-pass after oral adminis­
tration occurred,but to a small extent. The delivery of 
fenbendazole directly into the abomasum did, by contrast, result in 
markedly lower plasma concentrations of both fenbendazole and its 
metabolites. However, as discussed earlier in Chapter 3, the 
experimental administration of drugs into the abomasum via a cannula 
is probably not a good model for studying the fate of drugs diverted 
there via the reticular groove.
The metabolic route of the two sulfide drugs, fenbendazole 
and albendazole, to a sulfoxide and a sulfone appears to be similar. 
It is almost certain that there are several other metabolites,, but 
careful comparison of the results presented here v/ith studies using
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labelled benzimidazole leads to the conclusion that the greater 
part of the metabolites has been accounted for. Smith Kline have 
also confirmed that the major metabolites of albendazole in sheep 
[and in most other species) are those measured in this study 
(Theodorides - personal communication).
The in vitro investigation of the site of benzimidazole 
metabolism demonstrated clearly that no oxidation of fenbendazole or 
albendazole to their respective sulfoxides or sulfones occurred in 
either ruminai fluid or abomasal fluid. Substantial metabolism, 
however, occurred on incubation with hepatic microsomal enzymes.
This confirms the site of metabolism as being the liver, and is in 
accordance with the sheep studies in vivo, where the presence of 
sulfoxides was not confirmed in ruminai fluid. Although sulfoxide 
may have been present in low concentrations in ruminai fluid, belorw 
the limit of detection of the method, it was certainly not present 
in the concentrations one would expect if the rumen was the site 
of metabolism.
There are differences in the rate and extent of metabolism of 
fenbendazole and albendazole. The virtual absence of albendazole 
from the plasma of sheep after dosing suggests an extremely rapid and 
almost total conversion of the parent drug. Fenbendazole was present 
in plasma for a similar period as the sulfoxide, suggesting a slower 
rate of metabolism.
This was borne out by the results of the in vitro 
incubations with bovine hepatic microsomal enzymes when both drugs 
were incubated with microsomes from the same batch, the conversion
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of albendazole to its sulfoxide was greater and more rapid than that 
of fenbendazole.
Plasma concentrations of albendazole sulfoxide after 
albendazole administration, and of oxfendazole after fenbendazole 
administration, were in both cases much greater than those of the 
parent drug, Sulfone concentrations were substantially lower than 
those of sulfoxide for most of the time for which drug was present. 
Only in the later samples, 48 hours and after, did sulfone 
concentrations approximate to those of sulfoxide.
In the abomasum also high concentrations of sulfoxides 
were found; in the case of albendazole these were also higher than 
those of parent drug. Since metabolite formation was outwith the 
gastro-intestinal tract, passive diffusion across the wall of the 
abomasum must have been the mechanism involved. Since equivalent 
concentrations were not found in ruminai fluid, secretion via 
saliva is unlikely to have been implicated; and as benzimidazoles 
are basic drugs they are probably not secreted in saliva (pH 8,2) 
to any great extent.
It is unfortunate that the problems encountered in the 
analysis of rumen samples være never overcome sufficiently to be 
able to detect the low concentrations of metabolites which could be 
accurately measured in plasma and abomasal fluid. The only 
conclusions to be drawn are that sulfoxides did not reach concen­
trations greater than 0.2 pg/ml and sulfones not greater than 
0.05 pg/ml, It is not possible to state categorically that
diffusion of low amounts of sulfoxides back into the rumen from the
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systemic compartiront did not occur, but certainly the diffusion is 
relatively unimportant.
Passive diffusion of the sulfone metabolites into abomasal 
fluid was noted with both fenbendazole and albendazole, although to 
a lesser extent than the sulfoxides; the ratio of sulfoxide to 
sulfone concentrations in abomasal fluid was greater than that seen 
in plasma.
The appearance of low concentrations of fenbendazole in 
the plasma of sheep dosed with oxfendazole was at first thought to 
arise from the reduction of oxfendazole by ruminai micro-organisms 
which was seen during the in vitro incubation of rumen fluid with 
the drug. When oxfendazole was later incubated with bovine hepatic 
microsomes, however, there also appeared to be some conversion to 
fenbendazole. This rather surprising finding was confirmed by the 
subsequent publication by Douch and Buchanan C1979) who had found 
the same reaction to occur in mouse liver microsomes. The relative 
contributions of liver and ruminai reductions of oxfendazole to the 
measured concentration of fenbendazole in plasma cannot be determined 
from the limited results presented here.
Albendazole sulfoxide was also metabolised to its parent ' 
drug during in vitro incubation with ruminai fluid. It is not 
known whether albendazole is present in the plasma of animals dosed 
with the sulfoxide, but in view of the apparently rapid conversion 
of albendazole to its sulfoxide seen in vivo and in vitro this is 
thought to be extremely unlikely. Incubation of albendazole 
sulfoxide with bovine hepatic microsomal enzymes similarly yielded
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albendazole. It is likely that the apparent difference in the 
overall rates of conversion of albendazole and fenbendazole to their 
respective metabolites are due to differences in the relative rates 
of the oxidation/reduction reactions.
Species differences in rates of reaction may also explain the 
higher plasma concentrations of albendazole found in rats comoared 
with those in sheep during the present study. Alternatively this 
may have been due to faster absorption of albendazole in this 
species.
The kinetics of oxfendazole when given to sheep as 
oxfendazole were similar to those of oxfendazole formed metabolically 
from fenbendazole. Oxfendazole concentrations in plasma after 
administration of fenbendazole were between 30% and 50% of those 
found after administration of oxfendazole itself at the same dose 
rate and in the same six sheep.
The ratio of the concentration of oxfendazole to sulfone 
in plasma was similar after administration of either drug, suggesting 
that fenbendazole was converted to sulfone only via the sulfoxide and 
not directly.
The question as to which of these drugs or metabolites, if 
any, is anthelmintically active is of great interest. The virtual 
absence of circulating albendazole in sheep plasma together with its 
known activity against lungworm suggests that one or more of the 
metabolites may be the agent active in the lungs, Averkin, Beard,
Dvorak, Edv/ards, Fried, Kilian, Schiltz, Kistner, Drudge, Lyons, Sharp ar 
Corwin (1975) have shown the sulfoxide of the analogous drug fenbencazolE
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to be more potent than fenbendazole itself; and numerous 
parasitological trials have proved the efficacy of oxfendazole in 
ruminants.
The results of the studies performed here in rats show 
that albendazole sulfoxide is as anthelmintically active as albendazole 
itself. Unfortunately the attempts at inhibiting the in vivo 
metabolism of albendazole were unsuccessful. In the first trial 
the repeated injection of piperonyl butoxide resulted in poor and 
variable intake of the drug. In the second trial the larval 'take' 
as evidenced by low adult worm burdens in the control animals was 
probably insufficient to be able to dravj any valid conclusions as 
to the relative activities of the two compounds. The sulfone of 
albendazole was found to be non-active and this is in agreement with 
the study by Averkin et al (1975) in which the sulfone of fenbendazole 
was reported to be poorly active.
Consideration of the relative concentrations of parent 
drug and metabolites found in vivo suggest that much of the anthel­
mintic activity is related to the sulfoxides. In both plasma and 
abomasal fluid albendazole sulfoxide was quantitatively rrare 
important than the parent drug, and in plasma although not in 
abomasal fluid, oxfendazole was present in higher concentrations than 
fenbendazole.
The possibility exists that neither the sulfide nor the 
sulfoxide is the 'active' metabolite. There is increasing 
evidence that many of the metabolites which are cytotoxic are highly 
reactive intermediates such as epoxides or free radicals with very
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short half-lives and it has been suggested that hydroxylation of 
oxfendazole occurs via an epoxide intermediate [Bell and Tomlinson, 
19763, Should the 'active' metabolite of the benzimidazole drugs 
prove to be such a highly reactive intermediate it will probably be 
formed by the helminth, locally since it is unlikely that the 
required concentrations would be found at the many diverse 
predilection sites of parasites known to be killed by the 
benzimidazoles. Oxidation of fenbendazole to oxfendazole, and of 
albendazole to its sulfoxide and, in this case, sulfone has been 
shown to occur during incubation of the parent drugs with nematodal 
and cestodal enzymes [Douch and Buchanan, 1979). It is interesting 
that the same authors report that sulfoxidases of helminths have 
some properties simdlar to those of guinea pig liver [a requirement 
of NADPH and oxygen), whereas sulfoxide reductases of helminths are 
unlike those of marrmalian systems. It is possible that the 
remarkable selectivity of benzimidazoles for helminths may be 
related to differing metabolic routes possibly involving different 
intermediates. Although the sulfides or sulfoxides may not prove 
to be the compounds ultimately toxic to the helminths, it is never­
theless clear that they will be associated with concentrations of ' 
such a metabolite and that kinetic studies such as these would still 
be appropriate.
CHAPTER B 
GENERAL DISCUSSION
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The major part of this study became, in effect, a detailed 
investigation of the pharmacokinetics of the more recent benzimidazole 
anthelmintics, drugs which are unusual in both their physical properties 
and pharmcokinetic behaviour; however there are a few general observa­
tions to be made from the results as a whole. One of the original 
aims of the project was to assess the importance of the rtiminal 
epithelium as a possible site of drug absorption in the normal animal,
The evidence from the available literature suggested■that absorption 
from the rumen could occur by passive diffusion, but,none of the experimental 
models used allowed any conclusions to be drawn as to the extent of this 
process under the normal conditions of the ruminant gut.
The evidence presented in this thesis is conflicting; the 
meclofenamate experiments, particularly the tied-off rumen study, 
demonstrated that no significant absorption of this drug occurred from 
the rumen, although since meclofenamic acid is an acidic drug, in the 
acidic environment of the ruræn conditions would have been thought to 
be favourable for absorption. By contrast, levamisole administered 
intra-ruminally was detected in plasma before it was detected in abomasal 
fluid, suggesting that some absorption occurred prior to drug reaching 
the abomasum/sma11 intestine. This is rather surprising as being a 
basic drug levamisole would have been expected to be less likely to be 
absorbed at this site than meclofenamate.
• One possible explanation for the failure of absorption of 
meclofenamic acid is that at the pH of rumen contents [approximately 
6.6), the degree of ionization of the drug is so high [>99.6%) that the
1B4
large ratio of ionized drug;unionized drug limits the rate of
absorption. The lowest pk^ value for a weak acid which is compatible
with rapid absorption from the small intestine [the contents of which
also have a pH of around 6.6) is pk^ 3 CHogben et al, 1959). For
acids with a lower pk^ value, the degree of dissociation appears to
be the limiting factor in their rate of absorption. However, if there
is a more acidic zone CpH 5.3) at the site of absorption from the
intestine, as has been suggested (Hogben et al, (1959), and if no such
acidic zone exists in the rumen, then the pk values at which thea
degree of dissociation becomes limiting for absorption will be different 
for these two parts of the gut.
With an absorbing pH of 5.3 the maximum ratio of ionized; 
unionized drug for both acids and bases which is compatible with rapid 
absorption appears to be 200:1. For meclofenamic acid Cpk^  3.76) in 
ruminai fluid the ratio of ionized:unionized drug would be almost 
700:1, which is well outside this limit. For levamisole by contrast, 
although it is a weak base, the ratio of ionized .-unionized drug would be 
approximately 25:1.
All the results presented, hov/ever, are in agreement with the 
hypothesis that absorption from the rumen, if it occurs, is greatly 
slower than that from the lower parts of the gastro-intestinal tract. 
With all of the drugs studied, plasma concentrations rose more rapidly 
following oral or intra-abcnasal administration than after intra- 
riminal administration.
This rapid rise in plasma concentrations of drug after oral 
administration compared with intra-nminal administration is almost
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certainly due to a proportion of orally administered drug being diverted 
directly to the abomasum/strall intestine by the action of the reticular 
groove. With all the drugs studied, on almost every occasion on which 
oral administration was nade to any of the sheep, drug was detected 
in the abomasal fluid by 10 minutes after administration. In sheep 
with duodenal as well as aborrasal cannulae, it was found that drug 
by-passing the rumen via the groove also reached the small intestine.
This is in agreement with the findings of earlier workers who used 
dye administration and slaughter methods to investigate reticular 
groove function CClunies Ross, 1931),
The extent of ruminai by-pass was, on the evidence of abomasal 
fluid concentrations, extremely variable and apparently not consistent 
for any individual sheep; nor did it appear to increase with repeated 
administration. Since the closure of the groove has been shown to be 
due to a conditioned reflex associated with the desire to take milk in 
the suckling animal, and as such diminishes as the animal assumes adult 
feeding babits C0rskov et al, 1970) it would not be expected that the 
groove would function efficiently during forced drenching. These 
experimental findings probably approach the field situation for anthel­
mintic drugs, in which animals are drenched at intervals, and it can be 
concluded that in these animals also, a variable, usually small, 
proportion of the drench is probably diverted by the groove. The 
importance of groove function in relation to loss of anthelmintic 
efficiency of the benzimidazole drugs has therefore been over-emphasized. 
The results presented in this thesis demonstrate very clearly that 
administration of drugs into the abomasum via a cannula does not mimic
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the natural functioning of the reticular groove during dosing. This 
is probably due to deposition of drug in the omasum during closure of 
the groove. This organ has received little attention as regards its 
effect on orally administered~drugs but it is likely that insoluble drugs 
especially may be deposited in the laminar folds and provide a further 
reservoir of drug supplying the abomasum/small intestine. ' Similarly, 
differences between the kinetics of drugs following the reticular 
groove and those administered by the technique of intra-abcmasal 
injection are likely to occur, and the limitations of such studies should 
be recognized.
The concept of the rumen providing a ’reservoir' of drug is 
well supported by the findings of this study. Even drugs administered 
as solutions were generally still detectable in ruminai fluid by 22-24 
hours after oral or intra-ruminal administration, and the highly 
insoluble drugs remained for several days. If the overall effect of 
the rumen on orally administered drugs is one of dilution and slow 
delivery of drug to the distal parts of the gastro-intestinal tract, it 
is probable that any condition causing depression of ruminai motility 
will also affect the rate of absorption and therefore possible thera­
peutic effect.
One recurrent finding throughout this study was the large 
individual variation in drug concentrations in plasma, and in the 
various gut compartments after a similar dose, A general observation 
was that animals which were in poor bodily condition had much higher 
gut and plasma concentrations than those in good condition. This was 
presumably a result of the small volume of rumen contents associated
187
with low feed intake in these animals. The relatively lower proportion 
of muscle and fat tissue would account for the higher plasma concentrations, 
since redistribution of drug in plasma into muscle and fat is for many 
drugs an imjDortant influence on plasma concentrations.
This large variation seen in individual animals has obvious 
implications in that an effective dose in one animal will be ineffective 
in another and an overdose in yet another. This is probably of greater 
importance for drugs administered orally for a systemic effect, than 
those aimed at the gastro-intestinal tract, where minimum effective 
concentrations for most drugs are probably more readily achieved by 
this route.
Another aspect of ruminant pharmacology which was of interest 
in this project was that of passive diffusion of drugs from the systemic 
corrpartment into the rumen, and their possible accumulation there by 
the process of ion trapping. There are two possible routes by which 
drug present in plasma can reach the rumen; either by diffusion across 
the rumen wall, or by diffusion into saliva which is subsequently 
swallowed into the rumen. For drugs which diffuse readily into saliva, 
the amounts reaching the rumen in this way could theroetically be 
significant when it is considered that the volume of saliva produced 
per day in sheep can be up to six times the plasma volume. Drugs 
which are unaffected by passage through the rumen will be available 
for re-absorption from the gut, any that are susceptible to microbial 
degradation will not, and for such drugs salivary excretion may be an 
important route of elimination.
Levamisole and meclofenanate were detected in rumen fluid
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after subcutaneous and intra-abomasal administration respectively. It
would be expected that rroclofenamate being an acidic drug would be
more likely to reach the rumen via accumulation in the alkaline
(pH 3.2) saliva, and that levamisole being a weak base would be
trapped in ruminai fluid by diffusion acorss the rumen wall. However
it is possible that the predicted high ratio of ionized to unionized
meclofenamate in plasma would prevent ready diffusion of the drug
into saliva, and it is also possible that levamisole is secreted in saliva
to a certain extent since, although the equilibrium ratio would be 3:1
in favour of plasma, the constant secretion of saliva would ensure
that equilibrium would not be achieved.
Unfortunately, since salivary excretion of drugs was not 
measured curing this study, it is impossible to assess the relative 
contributions of the two possible routes by which these drugs entered 
the rumen after intra-abomasal or subcutaneous administration. It 
is interesting that ruminai fluid concentrations of levanisole in 
this situation did not nearly approach the theoretical equilibrium 
distribution concentrations (calculated ratio approximately 5:1 in 
favour of ruminai fluid). Concentrations of meclofenamate in the 
rumen did achieve the expected ratio, but only in a very few samples, 
and in some animals the drug was not detectable in ruminai fluid 
for much of the sampling period.
Accumulation in the rumen v;as not a feature of the 
benzimidazole drugs; neither intra-abomasally administered fenbendazole 
nor any of the systemically formed metabolites reached detectable 
concentrations in this compartment. In the abomasum, by contrast.
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sulfoxides attained concentrations of up to ten tines those present 
in plasma, and albendazole sulfone and subcutaneously administered 
levamisole were also found to be concentrated there, presumably due to 
ionization of these drugs in the acidic environment.
The question of accumulation of systemically formed compounds 
and parenterally administered drugs in the abomasum is of interest, 
particularly with regard to anthelmintics administered for the treat­
ment of gastro-intestinal helminthiasis. It is generally assumed 
that the important concentration for such an anthelmintic is that 
achieved in the gut. However, larvae buried within gastric glands 
may well be more accessible to anthelmintic in plasma than to drug in 
the lumen of the gut. Even adult worms have a fairly close 
association with the mucosal surface which, particularly in the small 
intestine, has a very extensive capillary network closely underlying 
the surface epithelium, and it is possible that even if these drugs 
did not accumulate in the gut fluid they would still be anthelmintically 
effective. In heavy parasitic infection of the abomasum, notably 
that of ostertagia spo, the pH of abomasal fluid may rise considerably, 
and it would be expected that the concentrations of systemically 
administered or metabolically formed drug found in the abomasal fluid 
of such animals would be lower than those found in the experimental 
animals.
Minimum effective concentrations of anthelmintics are 
difficult to establish in vivo, and parasites may have different 
susceptibilities to anthelmintic during in vitro incubations from those 
found for the same woim in the natural environment of the host. However
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a log dose response relationship has been shown for the efficacy of 
levamisole against adult N. braziliensis in vitro (Coles et al, 1975). 
These authors found inactivation of 100% of the worms after three 
hours of incubation with levamisole at a concentration of 1 yg/ml, and 
after six hours of incubation with 0.5 yg/ml. These concentrations 
are of the same order as those achieved in sheep plasma during the 
present study with levamisole administered by all three routes, 
at the normal therapeutic dose. The abomasal fluid concentrations 
wero several times greater than this, even after subcutaneous adminis­
tration of the drug. Coles et al (1975) also found recovery of 
motility of adult worms on continued incubation with the drug, and it 
would appear that prolonged exposure of the parasites to the drug would 
not increase its efficacy indefinitely. Should the parasites not be 
expelled by the host during the paralysed phase, clinical cure might 
well not be achieved.
Minimum effective concentrations of the benzimidazole drugs 
are, for several reasons, even more difficult to establish. Their 
mode of action seems to be via their effects on the microtubular 
system of the parasite cell, deterioration of which causes blockage 
of the movement of secretory granules and impaired digestion and 
absorption of nutrients. This sequence of events would be expected 
to occur over a period of time and the stage at which the changes 
become irreversible is unknown. Ultrastructural changes in intestinal 
cells of Ascaris suum have been demonstrated after 6-9 hours of 
exposure to mebendazole (Borgers et al, 1975), Significant inhibition 
of glucose uptake by the same parasite has been found in vitro after
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incubation for 24 hours with 0.05 yg/ml of mebendazole (Van den 
bossche and De Nollin, 1973),
The results of the present investigation make determination 
of the minimum effective concentration even more complex. Assuming 
that the more recent benzimidazoles have a similar mode of action 
to that of mebendazole, the findings suggest that it is not unchanged 
benzimidazole but a sulfoxide or some further intermediate metabolite 
which binds to the nematode tubulin. If an intermediate metabolite 
is involved, it is likely to be formed by the helminth itself, 
possibly using mammalian-formed sulfoxide as the substrate. In this 
case the availability of substrate and the rate of its metabolism by 
the helminth will determine the efficacy of the drug.
No recovery of worre incubated with mebendazole has been 
found, although development of resistance over several generations of 
parasites is a well established phenomenon with benzimidazole drugs, 
and cross resistance between members of the group also occurs 
(Hogarth-Scott, Kelly, Whitlock, Thompson, James and Mears, 1975).
The failure of most anthelmintics to kill inhibited larval 
stages of nematodes has long been a stumbling block in the control 
of parasitic infection of cattle. The reason for their resistance 
to anthelmintic treatment is thought to be the extremely low 
metabolic rate of the larvae, with resultant low drug/parasite 
interaction. The greater duration of exposure cf these parasites 
to the more recent benzimidazole anthelmintics, even after a single 
oral dose of the drugs, is the probable explanation of their greater 
efficacy against these inhibited larvae. Prolonged administration
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of these drugs by the use of feedblock preparations or slow release 
rumen bullets will probably increase the larval kill even further.
Why inhibited larval stages of sheep nematodes are apparently much 
more susceptible to anthelmintics, even thiabencazole and levamisole, 
than those of cattle is not known.
The differences in kinetics and modes of action Of the two 
major groups of anthelmintics are also responsible for their differing 
toxicities in the host species. Levamisole acts on mammalian ganglia as 
it does on those of the helminth, and its therapeutic index is relatively 
low. Mebendazole is reported to have no effect on the microtubular 
system of the host cell CEorgers, De do11in, Verheyen, De Erabancer 
and Thienpont, 1975), although a related drug methyl(5-2-thienyl- 
carbonyl-H benzimidazol-zyl) carbamate with antitumoural activity 
appears to act by interfering with microtubules in mammalian cells 
(De Brabander, Van de Veire, Aerts, Gevens, Borgers, Desplenter and 
De Cree, 1975). It is possible that the extremely low toxicity of 
these compounds is entirely due to their kinetics. Because of their 
limited solubility, gastro-intestinal fluid will saturate with 
dissolved drug. Thus further increases in oral dosage will net result 
in increased absorption and toxicity. An LD^^ is not measurable for 
fenbendazole and is high for albendazole, 100 mg/kg in sheep and 
>1320 mg/kg in rats. This may well be a result of the higher plasma 
concentrations of albendazole metabolites compared with those cf 
fenbendazole and its metabolites, as found in this study. The lower 
toxicity in monogastric animals is also in agreement with this thecn,', 
lower concentrations of albendazole + metabolites being found in rats
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and in dogs [unpublished) than in sheep.
Some of the benzimidazole drugs are much more toxic to 
the developing embryo. Cambendazole, parbendazole, mebendazole,
albendazole and oxfendazole have all been shown to be teratogenic 
at doses far below the maximum tolerated dose in the adult (Delatour, 
1980). Usually the period of risk is quite limited. Interestingly, 
fenbendazole has not been found to have teratogenic effects although 
its major metabolite oxfendazole has, possibly the rate and degree 
of absorption of fenbendazole is insufficient to produce embryotoxic 
concentrations of oxfendazole.
The ideal approach to chemotherapy of both bacterial and 
parasitic infections is the synthesis of compounds which are 
selectively toxic to some structure or physiological mechanism 
possessed by the foreign agent and not the host, and this has long 
been recognized. Once such a compound is synthesized it must also 
reach an effective concentration at its site of action. Studies 
such as this serve to emphasize the complexity of the processes 
involved in achieving this apparently simple goal in the ruminant 
species.
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